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 Oxidative stress plays a major role in development of osteoporosis, in part, by 
suppressing the differentiation and function of bone forming osteoblasts.  This finding 
suggests that strategies to prevent or reverse osteoporosis may lie in targeting the 
osteoblast antioxidant response.  Quercetin is an antioxidant flavonoid found abundantly 
in the diet and in supplements, and is known to induce expression of antioxidant response 
genes and proteins in a variety of cell types.  The purpose of these studies was to examine 
the extent that quercetin metabolites up-regulate the antioxidant response, to identify cell 
signaling pathways that might be involved, and to examine the extent that quercetin 
preserves development of the osteoblast phenotype when cells are cultured in an 
oxidative stress environment.   We hypothesized that quercetin metabolites would up-
regulate the antioxidant response, and that this up-regulation would protect cells from 
oxidative stress-induced suppression.  Studies were performed in osteoblast-like cultures 
isolated from fetal rat calvaria that were treated with 0 to 20 µM quercetin aglycone 
(QRC), isorhamnetin (ISO), quercetin-3-O-glucuronide (Q3G) or a 2:1:1 mixture of all 
three metabolites (10 µM Q3G: 5 µM QRC: 5 µM ISO).  The antioxidant response was 
assessed by measuring expression of antioxidant genes and proteins.  Results indicated 
that QRC and ISO robustly up-regulated expression of two antioxidant response genes 
and proteins, heme oxygenase-1 (HO-1) and the catalytic subunit of γ-glutamate cysteine 
ligase, but Q3G had no effect.  Cell signaling protein, ERK1/2, and transcription factor 
NFκB proteins were also down-regulated by quercetin.  To examine the effect of 
 
 
quercetin on oxidative stress-induced suppression of osteoblast phenotype, cells were 
pretreated 12h with 20 µM QRC followed by incubation with 0 or 300 µM hydrogen 
peroxide, a known inducer of oxidative stress.  Differentiation was assessed by alkaline 
phosphatase staining and expression of osteoblast phenotypic gene markers.  Pretreating 
cells with 20 µM QRC partially blocked hydrogen peroxide-induced suppression of 
osteoblast phenotype, as indicated by higher levels of alkaline phosphatase staining and 
gene expression of osteoblast phenotype markers compared to cells pretreated with 0 µM 
QRC.   QRC also partially blocked hydrogen peroxide-induced up-regulation of HO-1.  
These results suggest that quercetin produces a low grade antioxidant response that 
“primes” cells to withstand a subsequent oxidative stress event, which protects 
development of osteoblast phenotype.  These findings offer important insight into the 
osteoblast antioxidant stress response, and support a link between osteoblast stress 
signaling and phenotypic development.    
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CHAPTER I 
 
INTRODUCTION 
 
 
Overview 
 
More than 40 million Americans are at high risk to develop, or have been 
diagnosed with osteoporosis (1).  Osteoporosis results in debilitating fragility fractures, 
and direct medical costs associated with these fractures are expected to exceed $25 
billion by 2025 (2).  Oxidative stress contributes to bone fragility, in part, by directly 
suppressing the phenotypic development and function of bone-forming osteoblasts (3-5).  
Concurrently, a diet high in antioxidant-rich, plant-based foods appears to be associated 
with higher bone density (6,7).  Taken together this evidence supports the investigation of 
the effects of antioxidant flavonoids on the antioxidant response and phenotypic 
development of osteoblasts.    
 Quercetin is one of the most abundant flavonoids found in plant-based foods, and 
has been shown to protect bone health in animal studies.  In ovariectomized rodent 
models of estrogen deficiency-induced bone loss, quercetin or quercetin-rich food 
extracts administered in the diet resulted in higher bone density (8), higher bone strength 
(9), and improved microarchitecture (10) compared to estrogen deficient ovariectomized 
controls that did not receive quercetin. Therefore, quercetin appears to be a viable target 
molecule to investigate the extent that flavonoids prevent or reverse osteoporosis via 
osteoblast-specific mechanisms.   
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 Previous studies investigating the effects of quercetin on osteoblasts are limited 
and contradictory, where some studies show stimulation of alkaline phosphatase activity 
(11), up-regulated osteoblast phenotypic gene markers, and calcium deposition (12), but 
other studies show that quercetin stimulates apoptotic cell death (13,14).  Additionally, 
many in vitro studies have primarily included only one quercetin metabolite, despite the 
fact that quercetin is enzymatically modified in the gut and liver such that there are 
multiple metabolites found in blood plasma after ingesting quercetin.  There have also 
been no studies, to our knowledge, specifically examining the effect of quercetin on the 
osteoblast antioxidant response and its signaling pathways during oxidative stress.  
 In other cell types, quercetin appears to protect cells from oxidative stress by 
activating the transcription of antioxidant response genes, which code for proteins 
involved in redox homeostasis (15-17).  This response is classically thought to be 
mediated by transcription factor Nrf2, which binds to antioxidant response elements in 
the promoter region of these genes.  However, other proteins, such as the mitogen-
activated protein kinase ERK1/2, and transcription factor NFκB have been shown to have 
overlapping roles in the antioxidant response and osteoblast phenotype development (18-
20), but the relationship of these proteins to the osteoblast antioxidant stress response and 
quercetin treatment is largely unknown.    
Research Hypothesis and Specific Aims 
The overall objective of this project is to examine the potential benefits of dietary 
antioxidant flavonoids, such as quercetin, on phenotypic development and function of 
osteoblasts, and to examine the mechanism by which quercetin interacts with the 
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osteoblast antioxidant response.  The central hypothesis is that quercetin metabolites will 
up-regulate the antioxidant response and preserve osteoblast development in fetal rat 
calvarial cells cultured in a high oxidative stress environment.     
 The first specific aim is to characterize the extent to which plasma quercetin 
metabolites up-regulate the antioxidant response of osteoblast-like fetal rat calvarial cells, 
with the hypothesis that one or more quercetin metabolites will up-regulate the 
antioxidant response.  The second specific aim is to identify potential signaling pathways 
involved in quercetin-induced alterations in the antioxidant response.  We hypothesize 
that the antioxidant response will involve alterations in at least one of the following 
pathways: Nrf2, ERK1/2, and NFκB, which are all involved in stress signaling and have 
overlapping roles in osteoblast phenotypic development.  The third specific aim is to 
examine the extent that quercetin preserves phenotypic development and alters the 
antioxidant response of osteoblasts cultured in an oxidative stress environment, with the 
hypothesis that quercetin will preserve the osteoblast phenotype and block activation of 
the antioxidant response when cells are in a suppressive, oxidative stress environment.   
This study is the first to use a primary osteoblast cell model treated with several 
quercetin metabolites to investigate the effects of quercetin on the antioxidant response 
and phenotypic development in osteoblasts cultured in an oxidative stress environment.  
This study provides a greater understanding of how flavonoids interact with bone cells 
under oxidative stress, which will provide evidence that supports development of 
antioxidant interventions that prevent or reverse osteoporosis.  Additionally, this work 
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contributes to a broader understanding of how specific food components interact with 
cells to prevent or reverse human disease. 
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
 
Oxidative Stress Suppresses Phenotypic Development of Osteoblasts   
 
Oxidative stress plays a major role in the development of osteoporosis.  The aging 
process (21,22) and menopausal estrogen deficiency (4,5), two risk factors associated 
with the development of osteoporosis, both result in oxidative stress in the osteoblast.  
Oxidative stress in osteoblasts is characterized by increased production of free radicals 
that results in damage to various cellular organelles, and can lead to cell death (19,23).  In 
this condition, cells generally respond by up-regulating genes and proteins involved in 
maintaining redox homeostasis and protecting the cell from the damaging free radicals 
(24-26).  Evidence demonstrates that transcriptional pathways that confer redox 
homeostasis also interfere with transcriptional pathways that regulate the osteoblast 
differentiation program (24), thereby suppressing osteoblast development and function.  
For example, the Forkhead box O (FoxO) family of transcription factors diverts an 
important scaffolding protein, β-catenin, away from the Wnt-signaling pathway, thus 
reducing Wnt/β-catenin signaling that is required for osteoblast differentiation (4).  
Similarly, the antioxidant response transcription factor, Nrf2, down-regulates osteoblast 
phenotype gene marker osteocalcin by physically binding to transcription  factor Runx2, 
the master regulator of osteoblast differentiation and preventing its activity (3).  Evidence 
also suggests that oxidative stress suppresses Maf transcription factors, shifting the
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differentiation of osteoblast precursor cells away from osteogenesis, and towards 
adipogenesis, further compromising the bone integrity (27).  Oxidative stress, therefore, 
appears to contribute to bone fragility by suppressing multiple differentiation pathways in 
osteoblasts and their precursors, which would inhibit formation of new bone.  Therefore, 
interventions that target alleviation of oxidative stress in osteoblasts may be an important 
strategy for preventing or reducing bone fragility seen in osteoporosis. 
Plant-based Diets Rich in Antioxidant Flavonoids Benefit Bone Health   
Plant-based foods that are high in antioxidants may impart protective effects on 
the skeleton.  Supporting this hypothesis, cross-sectional and epidemiological evidence 
indicate a positive association between high intake of antioxidant rich plant foods and 
bone health.  Prynne et al (6) showed that a 2-fold increase in intake of fruits and 
vegetables was associated with an approximately 6% increase in bone mineral density in 
the spine in girls, a 4% increase in the spine in boys, and an approximately 5% increase 
in the bone mineral content of the spine in older women.  Similarly, a cross-sectional 
study in post-menopausal Chinese women found a positive association between fruit and 
vegetable intake and bone density in the whole body and lumbar spine (28).  Studies 
investigating the relationship between bone health parameters and intake of specific 
antioxidant-rich foods show similar results.  Intake of onions, abundant in the antioxidant 
flavonol quercetin, was associated with approximately 5% higher BMD at the lumbar 
spine, total body, and total leg in peri- and post-menopausal, non-Hispanic, white women 
living in the United States (29).  Black tea, the primary source of flavonol intake in the 
United States (30), is also protective of bone mineral density in elderly women (31).  
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Only one study has directly evaluated the specific intake of flavonoids and bone health, 
and found a positive association between total flavonoid intake and bone mineral density 
in the femoral neck and lumbar spine in peri-menopausal women (32). These studies 
show that plant-based diets appear to be protective of bone health across the lifespan and 
in various ethnic populations.  Taken together, these data provide evidence that plant-
based flavonoids might be an effective way to prevent or reverse osteoporosis.   
Antioxidant Flavonoid Quercetin may Protect Bone Health 
Despite the positive association between plant-based foods and bone health, the 
cause of these observed effects remains unknown.  It has been hypothesized that 
antioxidant flavonoids in plant-based foods may ameliorate oxidative stress in 
osteoblasts.  Quercetin has received attention as a flavonoid that may impart multiple 
disease-preventive health benefits, whether administered as a supplement or in the diet 
(33).   Quercetin is an abundant flavonoid in the Western diet (34), and is found in many 
types of commonly consumed foods, such as onions (35), apples (36), and tea (30).  
Studies specific to osteoporosis typically have focused on the extent that quercetin or 
quercetin-rich foods prevent bone loss in ovariectomized rat models of post-menopausal 
osteoporosis.  These studies largely support the hypothesis that quercetin benefits bone 
health.  Quercetin-rich onion powder extract supplemented in the diet of ovariectomized 
rats resulted in lower trabecular separation and increased bone strength compared to 
ovariectomized controls (9).  Direct supplementation of quercetin aglycone in the diet 
resulted in higher bone density in the femur and L4 vertebra in ovariectomized mice (8), 
and improved microarchitecture (bone volume, trabecular separation, and trabecular 
  8 
 
number) in femur epiphyses of ovariectomized rats (10).  Additionally, biomechanical 
quality was improved by quercetin in osteopenic rat models of diabetes (37).  Studies 
such as these lend support to the idea that quercetin may be, at least in part, responsible 
for the positive association between plant-based food consumption and bone health.  
Furthermore, these studies make quercetin a viable target molecule for investigating the 
extent to which quercetin protects phenotypic development of osteoblasts during 
oxidative stress. 
Although animal studies suggest that quercetin protects bone health, the cellular 
target of quercetin in bone has not been fully elucidated.  In studies conducted with 
cultures of bone-resorbing osteoclasts, quercetin aglycone appears to induce apoptosis 
and reduce osteoclastic-activity (38,39), suggesting that quercetin may, in part, protect 
bone integrity by limiting bone resorption.  However, studies conducted in osteoblast cell 
models are often not congruent with evidence from animal studies, and report increased 
apoptotic cell death.  For example, in MC3T3-E1 cells, 20 µM quercetin aglycone 
stimulated Bax up-regulation and apoptosis (13), and 10 µM quercetin aglycone 
enhanced apoptosis in the MC3T3-E1 osteoblast cell line, but not in primary calvarial 
osteoblasts, when co-incubated alongside pro-apoptotic cytokine TNF-α (14).  In 
contrast, other studies show that quercetin directly stimulates osteogenic markers.  A 50 
µM dose of quercetin aglycone stimulated alkaline phosphatase activity in MG-63 cells, a 
human osteoblast line (11), and in human primary mesenchymal stem cells, pretreating 
with 5 µM quercetin aglycone before incubation with osteogenic media resulted in higher 
Alizarin red-stained calcium deposits and higher expression of osteoblast gene markers 
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(e.g. osteopontin, alkaline phosphatase, and Runx2) compared to cells without quercetin 
pretreatment (12).  The paradoxical evidence that quercetin aglycone causes both cell 
death and enhances osteogenesis, highlights the importance of further experiments to 
examine the relationship between quercetin, oxidative stress, and development of the 
osteoblast phenotype.   
The primary limitations of the previous studies in bone cells are the reliance on 
only one quercetin metabolite (the aglycone form), and doses that are outside of the range 
that is physiologically achievable in blood plasma from the diet.  Dietary quercetin is 
extensively metabolized by enzymes in the small intestine, liver, and kidneys to produce 
plasma metabolites that include not only the parent molecule, quercetin aglycone, but 
several sulfated, methylated, and glucuronidated conjugates (40).  Plasma concentrations 
of quercetin metabolites are difficult to absolutely determine, due to wide variability in 
experimental methodology between studies (e.g. administration method, animal species, 
detection method, and the molecular form of quercetin administered during treatment).  
For example, administering 50 mg quercetin aglycone per kg body weight by gavage 
resulted in peak total plasma metabolite concentration of 2.5 µM (41) in one study, but 
13.2 µM in a different study (42) after 1h in rats.  This same dose, when administered as 
0.1% (w/w) quercetin aglycone in the rats’ diet, resulted in 7µM total plasma metabolites 
(consisting of about 1.5 µM non-methylated metabolites and about 5 µM methylated 
metabolites) after 4 weeks of treatment (41) or up to 23.4 µM total plasma metabolites 
(consisting of 7.7 µM quercetin aglycone and 15.7 µM isorhamnetin) after 11 weeks of 
treatment (43).  Conversely, only 0.81µM total plasma quercetin metabolites were 
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measured in pigs fed 50 mg quercetin aglycone per kg body weight in a meals for 4 
weeks (44).   Median intake of quercetin in humans has been reported to range between 
7-33 mg/day (45), but has also been difficult to absolutely establish given variability in 
study designs, as well as individual and cultural food preferences (46).  Therefore, it is 
not clear as to whether the doses administered in pharmacokinetic animal studies are 
congruent with amounts of quercetin that would be regularly achievable in the human 
diet.  In clinical trials, high inter-individual variability in peak total quercetin plasma 
concentrations has been noted, and peak concentration for each plasma metabolite is also 
variable, but in the range of 45 to 600nM (35,47), and perhaps as high as 5 µM (48).   
Although this wide variability makes the physiological concentration of quercetin 
metabolites in the blood plasma difficult to determine with absolute certainty, these 
studies demonstrate that dietary or supplemented quercetin consumed orally will result in 
a maximum concentration in the blood plasma in the high nanomolar to low micromolar 
range.  Therefore, these experiments focused on doses of multiple quercetin metabolites, 
which are more reasonably achievable plasma concentrations attained from ingestion of 
quercetin or quercetin-containing foods.   
Quercetin Protects Cells from Oxidative Stress 
  There are currently no studies that have explored the relationship between 
quercetin and the oxidative stress response in osteoblast-like cells.  Studies in other cell 
types, however, provide evidence of the mechanism by which quercetin or its metabolites 
impact the cellular stress response of cells.  One of the primary targets of quercetin 
appears to be nuclear factor (erythroid-derived 2)-like 2 (Nrf2).  Nrf2 is a transcription 
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factor which, when activated by oxidative stressors, initiates transcription of stress 
response genes by binding to the antioxidant response elements (AREs) in the promoter 
region of these genes (49).  Relatively short-term treatment (0.5h to 48 h) of cells with 
quercetin aglycone (ranging from 1 to 100 µM) has been shown to up-regulate Nrf2 at 
both the transcriptional and post-translational level (15,17,26).  The quercetin-mediated 
up-regulation of Nrf2 protein results in increased binding to AREs, and subsequent 
transcription of genes involved in the stress response, such as NADPH:quinone 
oxidoreductase (15), heme oxygenase-1 (16,25), peroxiredoxins 3 and 5 (17), and the 
catalytic subunit of ɣ-glutamate-cysteine ligase (26).  In addition to up-regulating genes 
and proteins involved in the stress response, evidence also indicates that quercetin may 
detoxify free radicals by direct scavenging and subsequent interaction with the 
intracellular tri-peptide thiol, glutathione (50,51).  Functionally, quercetin is able to 
decrease free radical damage (50) and increase cell survival and function (25,25,51) in 
the face of oxidative stress by activating the cellular antioxidant response.   
 In addition to Nrf2, quercetin has been shown to alter phosphorylation of MAP 
kinase ERK1/2 and the p65 subunit of NFκB.  In previous studies in osteoblast cell lines 
quercetin appears to induce phosphorylation of ERK1/2.  For example quercetin induced 
phosphorylation of ERK1/2 up to 6h after treatment with 20 µM quercetin in MC3T3-E1 
osteoblasts (13), while in MG-63 osteosarcoma cells (11), 50 µM quercetin induced a 
transient phosphorylation of ERK1/2 after only 5 minutes.  In other cell types results are 
inconsistent despite similar doses (20-30uM) and time points (up to 24h) among studies.  
For example, quercetin suppressed phosphorylated ERK1/2 in primary cortical neurons 
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(52), but up-regulated phosphorylated ERK1/2 in BEAS-2B bronchial epithelial cells 
(53).  Further investigation of ERK1/2 is necessary since this pathway appears to have 
overlapping roles in both the antioxidant response of osteoblasts (19), and osteoblast 
differentiation (54).  Like ERK1/2, the p65 subunit of NFκB has been shown to be altered 
by the antioxidant response.  Several lines of evidence suggest that Nrf2 activators down-
regulate NFκB signaling (55), and this has also been shown in MC3T3-E1 osteoblasts 
(56), which suggests that activation of the antioxidant response may also be anti-
inflammatory.  This finding is of particular importance to bone, since inflammation has 
been shown to down-regulate development of the osteoblast phenotype and activate 
osteoclastic resorption.   
In bone, quercetin may alleviate oxidative stress in osteoblasts and play a role in 
preventing osteoporosis.  Protection of the osteoblast phenotype by quercetin may seem 
paradoxical since the stress response pathways that quercetin activates have also been 
implicated in the suppression of osteoblast differentiation (e.g. Nrf2, 3).  Indeed, this 
paradoxical effect has been observed in studies in bone cells that show quercetin is both 
pro-apoptotic and stimulatory of osteoblast phenotype markers.  This hormetic effect on 
cells, such that both protective anti-oxidant and damaging pro-oxidant effects are 
observed, depends on the dose and duration of treatment (57).  In this regard, it is 
hypothesized that consuming quercetin or quercetin-rich foods would result in low 
concentrations of plasma quercetin metabolites that may stimulate a low-grade 
antioxidant response.  Exposure to the relatively low quercetin doses would effectively 
prime the cells for a subsequent oxidative insult (e.g. hydrogen peroxide) without 
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producing accompanying suppression of osteoblast phenotype development or cell 
survival.
  14 
 
References 
 
 
[1] National Institute of Arthritis and Musculoskeletal and Skin Diseases.  Version 
current January 2011. Internet: 
http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/osteoporosis_ff.asp (accessed 
September 24, 2014) 
[2] Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence 
and economic burden of osteoporosis-related fractures in the Unites States, 2005-2025. J 
Bone Miner Res 2007; 22(3):465-75. 
[3] Hinoi E, Fujimori S, Wang L, Hojo H, Uno K, Yoneda Y. Nrf2 negatively regulates 
osteoblast differentiation via interfering with Runx2-dependent transcriptional activation.  
J Biol Chem. 2006;281(26):18015-24. 
[4] Almeida M, Han L, Martin-Millan M, O’Brien CA, Manolagas SC.  Oxidative stress 
antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell 
factor- to Forkhead box O-mediated transcription.  J Biol Chem. 2007;282(37):27298-
305.   
[5] Almeida M, Han L, Amborgini E, Bartell SM, Manolagas SC. Oxidative stress 
stimulates apoptosis and activates NFκB in osteoblastic cells via a PKCβ/p66shc 
signaling cascade: counter regulation by estrogens or androgens. Mol Endocrinol 
2010;24(10):2030-7.
  15 
 
[6] Prynne CJ, Mishra GD, O’Connell MA et al.  Fruit and vegetable intakes and bone 
mineral status: a cross-sectional study in 5 age and sex cohorts.  Am J Clin Nutr 
2006;83:1420-8.   
[7] Welch AA, Hardcastle AC. The effects of flavonoids on bone.  Curr Osteoporos Res. 
2014;12: 205-10.   
[8] Tsuji M, Yamamoto H, Sato T et al.  Dietary quercetin inhibits bone loss without 
effect on the uterus in ovariectomized mice.  J Bone Miner Metab 2009;27:673-81.   
[9] Huang T-H, Mühlbauer RC, Tang C-H et al.  Onion decreases the ovariectomy-
induced osteopenia in young adult rats.  Bone 2008;42:1154-63. 
[10] Siddiqui JA, Sharan K, Swarnkar G, Rawat P, Kuma M, Manickavasagam L, 
Maurya R, Pierroz D, Naibedya C.  Quercetin-6-C-β-D-glucopyranoside isolated from 
Ulmus wallichiana planchon is more potent than quercetin in inhibiting 
osteoclastogenesis and mitigating ovariectomy-induced bone loss in rats.  Menopause. 
2010;18(2):198-207. 
[11] Prouillet C, Mazière J-C, Mazière C, Wattel A, Brazier M, Kamel S.  Stimulatory 
effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase 
activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway.  
Biochem Pharmacol 2004;67:1307-13.   
[12] Kim YJ, Bae YC, Suh KT, Jung JS.  Quercetin, a flavonoid, inhibits proliferation 
and increases osteogenic differentiation in human adipose stromal cells.  Biochem 
Pharmacol 2006;72:1268-78. 
  16 
 
[13] Nam TW, Yoo CI, Kim HT, Kwon CH, Park JY, Kim YK. The flavonoid quercetin 
induces apoptosis and inhibits migration through a MAPK-dependent mechanism in 
osteoblasts. J Bone Miner Metab 2008;26:551-60. 
[14] Son Y-O, Kook S-H, Choi K-C et al.  Quercetin accelerates TNF-α-induced 
apoptosis of MC3T3-E1 osteoblastic cells through caspase-dependent and JNK-mediated 
pathways.  Eur J Pharmacol 2008;579:26-33. 
[15] Tanigawa S, Fujii M, Hou D-X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 
expression by quercetin.  Free Radic Biol Med 2007;42:1690-703 
[16] Boesch-Saadatmandi C, Loboda A, Wagner AE, Stchurska A, Jozkowicz A, Dulak J, 
Döring F, Wolffram S, Rimbach G.  Effect of quercetin and its metabolites isorhamnetin 
and quercetin-3-glucuronide on inflammatory gene expression: role of miR-155. J Nutr 
Biochem 2011;22(3):293-9. 
[17] Miyamoto N, Izumi H, Miyamoto R, Kondo H, Tawara A, Sasaguri Y, Kohno K.  
Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 
transcription pathway.  Invest Ophthlmal Vis Sci 2011;52(2):1055-63. 
[18] Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT. Bone 
morphogenetic proteins, extracellular matrix, and mitogen-activated kinase signaling 
pathways are required for osteoblast-specific gene expression and differentiation in 
MC3T3-E1 cells.  J Bone Miner Res 2002;17:101-10.   
[19] Bai X, Lu D, Bai J, Zheng H, Ke Z, Li X, Luo S.  Oxidative stress inhibits 
osteoblastic differentiation of bone cells by ERK and NF-κB.  Biochem Biophys Res 
Comm 2004;314:197-207.   
  17 
 
[20] Chen Q, Liu K, Robinson AR, Clauson CL, Blair HC, Robbins PD, Niedernhofer LJ, 
Ouyang H. DNA damage drives accelerated bone aging via an NFkB-dependent 
mechanism. J Bone Miner Res 2013;28:1214-28.   
[21] Rached M-T, Kode A, Xu L, Yoshikawa Y, Paik J-H, DePinho RA, Kousteni S. 
FoxO1 is a positive regulator of bone formation by favoring protein synthesis and 
resistance to oxidative stress in osteoblasts.  Cell Metab 2010;11:147-60.   
[22] Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, 
Kousteni S, O’Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. 
Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex 
steroids. J Biol Chem. 2007;282(37):27285-97.   
[23] Lee DH, Lim BS, Lee YK, Yang HC.  Effects of hydrogen peroxide on alkaline 
phosphatase activity and matrix mineralization of odontoblast and osteoblast cell lines.  
Cell Bio Toxicol 2006 22(1):39-46. 
[24] Arai M, Shibata Y, Pugdee K, Abiko Y, Ogata Y.  Effects of reactive oxygen species 
on antioxidant systems and osteoblastic differentiation in MC3T3-E1 cells.  IUBMB Life 
2007;59(1):27-33. 
[25] Chen T-J, Jeng J-Y, Lin C-W, Wu C-Y, Chen Y-C.  Quercetin inhibition of ROS-
dependent and –independent apoptosis in rat glioma C6 cells.  Toxicology. 
2006a;223:113-26. 
[26] Arredondo F, Echeverry C, Abin-Carriquiry JA, Blasina F, Antunez K, Jones DP, 
Go Y-M, Lian Y-L, Dajas F.  After cellular internalization, quercetin causes Nrf2 nuclear 
  18 
 
translocation, increases glutathione levels, and prevents neuronal cell death against an 
oxidative insult. Free Radic Biol Med.  2010;49:738-47. 
[27] Nishikawa K, Nakashima T, Takeda S, Isogai M, Hamada M, Kimura A, Kodama T, 
Yamaguchi A, Owen MJ, Takahashi S, Takayanagi H.  Maf promotes osteoblast 
differentiation in mice by mediating the age-related switch in mesenchymal cell 
differentiation.  J Clin Invest 2010;120(10):3455-65. 
[28] ChenY-U, Ho SC, Woo JLF.  Greater fruit and vegetable intake is associated with 
increased bone mass among postmenopausal Chinese women.  Br J Nutr 2006b;96:745-
51. 
[29] Matheson EM, Mainous III AG, Carnemolla MA.  The association between onion 
consumption and bone density in perimenopausal and postmenopausal non-Hispanic 
white women 50 years and older.  Menopause 2009;16:756-9. 
[30] Song WO and Chun OK.  Tea is the major source of flavan-3-ol and flavonol in the 
US diet.  2008 J Nutr;138:1543S–7S.  
[31] Devine A, Hodgson JM, Dick IM, Prince RL.  Tea drinking is associated with 
benefits on bone density in older women.  Am J Clin Nutr 2007;86:1243–7. 
[32] Hardcastle AC, Aucott L, Reid DM, Macdonald HM.  Associations between dietary 
flavonoid intake and bone health in a Scottish population.  J Bone Miner Res 2011; 26(5): 
941-7.   
[33] Boots AW, Haenen GRMM, Bast A.  Health effects of quercetin: from antioxidant 
to neutraceutical.  Eur J Pharmacol 2008;585:325-37. 
  19 
 
[34] Chun OK, Chung SJ, Song WO.  Estimated dietary flavonoid intake and major food 
sources of U.S. adults.  J Nutr 2007;137:1244–52. 
[35] Mullen W, Edwards CA, Crozier A.  Absorption, excretion and metabolite profiling 
of methyl-, glucuronyl-, glucosyl-, and sulpho-conjugates of quercetin in human plasma 
and urine after ingestion of onions.  Br J Nutr 2006;96:107-16. 
[36] He X, Liu RH. Phytochemicals of apple peels: isolation, structure elucidation, and 
their antiproliferative and antioxidant activities. J Agric Food Chem 2008;56(2):9905-10.   
[37] Liang W, Luo Z, Ge S, Li M, Du J, Yang M, Yan M, Ye Z, Luo Z.  Oral 
administration of quercetin inhibits bone loss in rat model of diabetic osteopenia.  Eur J 
Pharmacol 2011;670(1):317-24.   
[38] Woo J-T, NakagawaH, Notoya M, Yonezawa T, Udagawa N, Lee I-S, Ohnishi M, 
Hagiwara H, Nagai K.  Quercetin suppresses bone resorption by inhibiting the 
differentiation and activation of osteoclasts.  Biol. Pharm. Bull 2004;27(4) 504-9.   
[39] Wattel A, Kamel S, Prouillet C et al.  Flavonoid quercetin decreases osteoclastic 
differentiation induced by RANKL via a mechanism involving NFkB and AP-1.  J Cell 
Biochem 2004;92:285-95. 
[40] Mullen W, Rouanet J-M, Auger C, Teissèdre P-L, Caldwell ST, Hartley RC, Lean 
MEJ, Edwards CA, Crozier A.  Bioavailability of [2-14C]quercetin-4’-glucoside in rats.  
J Agric Food Chem. 2008;56:12127-37. 
[41] Kawai Y, Saito S, Nishikawa T, Ishisaka A, Murota K, Terao J.  Different profiles of 
quercetin metabolites in rat plasma: comparison of two administration methods. Biosci 
Biotechnol Biochem. 2009;73(3):517-23. 
  20 
 
[42] Justino GC, Santos MR, Canário S, Borges C, Florêncio MH, Mira L.  Plasma 
quercetin metabolites: structure-antioxidant activity relationships.  Arch Biochem 
Biophys. 2004;432:109-121. 
[43] de Boer VCJ, Dihal AA, van der Woude H, Arts ICW, Wolffram S, Alink GM, 
Rietjens IMCM, Keijer J, Hollman PCH.  Tissue distribution of quercetin in rats and pigs.  
J Nutr. 2005;135:1617-18. 
[44] Bieger J, Cermak R, Blank R, de Boer VCJ, Hollman PCH, Kamphues J, Wolffram 
J.  Tissue distribution of quercetin in pigs after long-term dietary supplementation.  J 
Nutr. 2008;138:1417-20. 
[45] Wang L, Lee IM, Zhang SM, Blumberg JB, Buring JE, Sesso HD.  Dietary intake of 
selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged 
and older women. Am J Clin Nutr; 2009:89(3):905-12.   
[46] Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources 
and bioavailability. Am J Clin Nutr 2004;79:727-47.  
[47] Egert S, Wolffram S, Bosy-Westphal A et al.  Daily quercetin supplementation dose-
dependently increases plasma quercetin concentration in healthy humans.  J Nutr 
2008;138:1615-21. 
[48] Olthof MR, Hollman PCH, Vree TB, Katan MB.  Bioavailabilities of quercetin-3-
glucoside and quercetin-4’-glucoside do not differ in humans. J Nutr. 2000;130:1200-03. 
[49] Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative 
stress. Free Rad Bio Med. 2009;47:1304-9. 
  21 
 
[50] Kim G-N, Jang H-D. Protective mechanism of quercetin and rutin using glutathione 
metabolism on hydrogen peroxide-induced oxidative stress in HepG2 cells.  Ann NY 
Acad Sci 2009;1171:530-7.   
[51] Suematsu N, Hosoda M, Fujimori K. Protective effects of quercetin against 
hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells. Neurosci 
Letters 2011;504:223-7. 
[52] Spencer JPE, Kuhnle GC, Williams RJ, Rice-Evans C. Intracellular metabolism and 
bioactivity of quercetin and its in vivo metabolites. Biochem J 2003;372:173-81. 
[53] Lee Y-J, Song J-H, Oh M-H, Lee Y-J, Kim Y-B, Im J-H, Lee S-H.  ERK1/2 
activation in quercetin-treated BEAS-2B cell plays a role in Nrf2-driven HO-1 
expression.  Mol Cell Toxicol 2011;7:347-55. 
[54] Matsushita T, Chan YY, Kawanami A, Balmes G, Landreth GE, Murakami, S.  Mol 
Cell Biol 2009;29(21):5803. DOI: 10.1128/MCB.01549-08. 
[55] Li W, Khor TO, Xu C, Shen G, Jeong W, Yu S, Kong A. Activation of Nrf2-
antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. 
Biochem Pharmacol 2008;76:1485-9. 
[56] Yamaguchi M Weitzmann MN. Quercetin, a potent suppressor of NF-κB and Smad 
activation in osteoblasts.  Int J Mol Med 2011;28(4):521-5. 
[57] Vargas AJ and Burd R. Hormesis and synergy: pathways and mechanisms of 
quercetin in cancer prevention and management.  Nutr Rev. 2010;68(7):418-28. 
 
  22 
 
CHAPTER III 
 
QUERCETIN METABOLITES UP-REGULATE THE ANTIOXIDANT RESPONSE IN 
OSTEOBLASTS ISOLATED FROM FETAL RAT CALVARIA 
 
 
Abstract 
 
Oxidative stress contributes to osteoporosis by directly suppressing differentiation 
of bone-forming osteoblasts, suggesting that antioxidants may prevent osteoporosis by 
targeting the osteoblast antioxidant response.  Quercetin, a flavonol found in many types 
of plant-based foods, is under investigation as an antioxidant with potential as a 
therapeutic strategy to prevent chronic diseases.  Little is known about its effects on the 
osteoblast antioxidant response.  This study aimed to examine the extent that quercetin 
metabolites alter antioxidant response genes and proteins in osteoblasts, and to examine 
the extent that quercetin alters cell signaling pathways, including nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2), p65 subunit of nuclear factor-kB (NFkB), and 
extracellular-signal related kinase (ERK) 1/2, all of which are involved in stress signaling 
and the antioxidant response.  Osteoblasts were isolated from fetal rat calvaria and treated 
with three different commercially available quercetin metabolites found in blood plasma 
after consumption of quercetin: quercetin aglycone (QRC), isorhamnetin (ISO), a 
methylated metabolite, or quercetin 3-O-glucuronide (Q3G), a glucuronidated metabolite, 
using doses up to 20 µM.  Alternatively, some cells received a 2:1:1 mixture of all 3 
metabolites (10 µM Q3G: 5 µM ISO: 5 µM QRC) to evaluate synergistic effects.  The 
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osteoblast antioxidant response was assessed by analyzing several antioxidant response 
genes and proteins.  Cell signaling proteins (Nrf2, ERK1/2, NFκB) were also analyzed.  
Results indicated that QRC and ISO, but not Q3G, up-regulated two antioxidant response 
genes, heme oxygenase-1 (HO-1) and γ-glutamate cysteine ligase catalytic subunit 
(GCLC), at the mRNA and protein level.  Synergistic effects of metabolites were not 
observed.  Up-regulation of HO-1 and GCLC were associated with suppression of 
phosphorylated ERK1/2 and down-regulation of NFκB, but no alterations were seen in 
the levels of Nrf2 protein levels.  Additionally, no major alterations were seen in total 
antioxidant capacity or glutathione levels.  This study offers important observations on 
the osteoblast antioxidant response in the presence of antioxidant quercetin.   
Introduction 
Oxidative stress has been implicated as a major contributing factor in a number of 
chronic diseases, including osteoporosis [1].  Oxidative stress directly suppresses the 
maturation and function of bone-forming osteoblasts [2], which along with increased 
osteoclastic bone resorption, leads to low bone mass and bone fragility observed in 
osteoporosis.  These findings suggest that preventive strategies for osteoporosis may lie 
in targeting the antioxidant stress response of osteoblasts.  Quercetin, a common 
antioxidant flavonoid found abundantly in many plant-based foods, has been investigated 
as an antioxidant that may prevent chronic diseases associated with oxidative stress [3].  
Furthermore, quercetin improves bone density [4], bone strength [5], and 
microarchitecture [6] in ovariectomized rodent models of estrogen deficiency bone loss.  
Additionally, quercetin-rich diets have been shown to be associated with higher bone 
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density in human populations [7].   Despite these findings, little is known about the effect 
of quercetin, or other antioxidants, on the osteoblast antioxidant response.   Therefore, the 
overall goal of this study was to address these gaps in knowledge.    
Quercetin aglycone has been shown to stimulate the antioxidant response in many 
cell types by activating the redox sensitive transcription factor, nuclear factor (erythroid-
derived 2)-like 2 (Nrf2).  Nrf2 imparts oxidative stress protection by binding to 
antioxidant response elements and initiating transcription of genes involved in protecting 
cells from environmental stressors [8].  Up-regulation of these endogenous antioxidant 
genes is thought to prime cells so that they may prevent damage from a subsequent 
oxidative insult.  Quercetin has been shown to up-regulate several antioxidant response 
genes in various cell types.  For example, quercetin up-regulates heme oxygenase-1 (HO-
1) in RAW264.7 macrophages [9] and glioma C6 cells [10], γ-glutamate-cysteine ligase 
catalytic synthetase (GCLC) in primary neurons [11], catalase, peroxiredoxins (Prdx) 3 
and 5 in trabecular meshwork cells of the eye [12], and NADPH:quinone oxidoreductase-
1 (NQO-1) in HepG2 cells [13].  While the effect of quercetin aglycone on Nrf2 
activation and up-regulation of the antioxidant response genes has been frequently 
reported, this has not been described in osteoblasts.  Furthermore, other signaling 
pathways with overlapping roles in osteoblast development and stress signaling have 
been identified, including mitogen activated protein kinase extracellular-signal related 
kinase (ERK) 1/2 [14,15] and the p65 subunit of nuclear factor-κB (NFκB), [15,16], but 
the effect of quercetin on these pathways has not been investigated fully in osteoblasts .   
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Most in vitro studies have primarily focused on quercetin aglycone even though 
quercetin and other flavonoids consumed in foods or supplements are extensively 
modified by enzymes in the gut and liver to produce a mixture of methylated, sulfated, 
and glucuronidated conjugates in the blood plasma [17].  In order to assess a more 
complete picture of the effect of quercetin metabolites found in blood plasma, in vitro 
studies are needed that describe the effects of multiple metabolites.  Therefore, the first 
specific aim of this study was to examine the antioxidant response and subsequent 
alterations in antioxidant capacity in osteoblasts exposed to both quercetin aglycone and 
enzymatically conjugated quercetin metabolites in osteoblast-like cells isolated from fetal 
rat calvaria.  We hypothesized that one or more of these quercetin metabolites would up-
regulate antioxidant response genes and proteins in these cells and that antioxidant 
capacity would therefore be altered.  The second specific aim of this study was to identify 
potential signaling pathways in the osteoblast antioxidant response, specifically 
alterations in Nrf2, ERK1/2, and NFκB.  We hypothesized that one or more of these 
signaling pathways would be altered by treatment with quercetin.  Since quercetin may 
have preventive effects on oxidative stress, these studies were designed to investigate 
stimulation of the antioxidant response from basal conditions in “normal,” developing 
osteoblasts.   
Materials and Methods 
Reagents 
Alpha-modified minimal essential media, fetal bovine serum, gentamicin, 
fungizone, dimethylsulfoxide (DMSO), and silver nitrate were purchased from Thermo 
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Fisher Scientific (Waltham, MA, USA).  Penicillin, collagenase, ascorbic acid, β-
glycerophosphate, dexamethasone, red violet LB salt, naphthol AS MX-PO4, hydrogen 
peroxide, tert-butylhydroquinone (tBHQ), quercetin aglycone (QRC), and isorhamnetin 
(ISO) were purchased from Sigma (St. Louis, MO, USA).  Quercetin-3-O-glucuronide 
(Q3G) was purchased from Extrasynthese (Genay, France) 
Animals and Diet 
 Timed-pregnant Sprague-Dawley rats were purchased from Harlan Laboratories 
(Indianapolis, IN, USA).  Dams were obtained on day (D) 4 of pregnancy and housed 
with a 12-hour light/dark cycle, and ad libitum access to water and Teklad soy protein-
free rodent diet (Harlan, 2920X).  A soy-free diet was used to avoid potential 
confounding effects of isoflavones found in soy on osteoblast development in utero.  The 
total isoflavone concentrations, as measured by the manufacturer, were 3 and 8 mg/kg for 
the batches used in this study, and were considered near the lower  limit of detection.  
Dams were euthanized on D21 of gestation by overexposure to CO2.  Fetuses were 
removed and placed in a petri dish on ice to induce hypothermia before decapitation and 
removal of calvariae (frontal and parietal bones) for cell isolation.  All procedures were 
reviewed and approved by the University of North Carolina at Greensboro Institutional 
Animal Care and Use Committee.   
Cell Culture 
To obtain osteoblast-like cells, calvariae were minced and subjected to five, serial 
incubations with collagenase to release cells from surrounding tissue.  Cells from the first 
incubation were discarded, while cells from the second through fifth digestions were 
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plated each in separate T75 flasks.  The following day cells were trypsinized, pooled, and 
plated at 3000 cell/cm2 in 6-well culture dishes.  Cells were incubated at 37°C under 5% 
CO2 for the duration of the experiment.  Cell culture media was changed every 2-3 days 
and consisted of alpha-modified minimal essential media supplemented with 10% fetal 
bovine serum, 10% antibiotic solution (penicillin, gentamicin, and fungizone), as well as 
ascorbic acid (50 µg/µL), β-glycerophosphate (10 mM), and dexamethasone (10-8 M) to 
induce osteogenesis.   
Fetal rat calvarial cultures undergo distinct proliferation and differentiation 
phases.   After plating, cells proliferate until confluence (approximately D5), which is 
followed by a 2-week differentiation phase (approximately D5-21), culminating in 
formation of discrete bone-like nodules that stain positive for cell-surface protein alkaline 
phosphatase, and secrete a collagen-based protein matrix that becomes mineralized.  
These cells also express genes that are characteristic of the osteoblast phenotype, 
including collagen type 1a, alkaline phosphatase, bone sialoprotein, and osteocalcin, as 
well as the master regulator of osteoblast differentiation, transcription factor Runx2 [18].   
Alkaline Phosphatase and von Kossa Staining 
These staining methods have been previously described [19].  Briefly, cells were 
washed in PBS, fixed in 10% neutral formalin buffer for 15 minutes, and rinsed with 
deionized water.  Alkaline phosphatase-positive cells were stained using Naphthol AS 
MX-PO4 as substrate and Red Violet LB salt as coupler.   
Mineralized nodules were visualized using the von Kossa method.  Alkaline 
phosphatase stained cultures were incubated with 2.5% (w/v) silver nitrate solution for 30 
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minutes, which results in brown/black staining of mineralized nodules.  Von Kossa 
staining was only performed at the end of culture (D21).  Culture dishes were then rinsed 
in tap water and air dried overnight.   
Bone Nodule Assays 
Wells were examined microscopically under bright field illumination and 
mineralized nodules were counted.  Mineralized nodules were areas of intense alkaline 
phosphatase stained, cuboidal cells that were also costained with von Kossa.   
Preparation of Stock Solutions 
QRC (Figure 1A), ISO (Figure 1B), a methylated metabolite, or Q3G (Figure 1C), 
a glucuronidated metabolite were dissolved in degassed DMSO and stored at -20°C.  For 
experiments using a mixture of metabolites, stocks were diluted at a 2:1:1 ratio of 10 µM 
Q3G: 5 µM QRC: 5 µM ISO.  This ratio was based on studies that show conjugated 
metabolites to be most prevalent in blood plasma after conjugation by enzymes in the gut 
and liver [20].  Hydrogen peroxide (30% w/v) was freshly diluted in sterile, deionized 
water just before use.  Quercetin metabolites at final concentrations up to 20 µM, and 
hydrogen peroxide at final concentration of 75, 150, or 300 µM were administered with 
fresh media.  Some cells were treated with tBHQ at final concentrations of 0, 20, or 40 
µM as a positive control.  The vehicle control (0 µM) for hydrogen peroxide was sterile, 
deionized water, and the vehicle control for quercetin metabolites and tBHQ was 0.1% 
(v/v) DMSO. 
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Quantitative Real-time PCR 
Cells were lysed in 900 µL of Qiazol using a cell scraper and lysate was 
transferred to microcentrifuge tubes.  RNA was isolated using RNeasy Universal Minikit 
(Qiagen, Valencia, CA, USA) per manufacturer’s instruction and quantified using a 
Nanodrop spectrophotometer.  Two micrograms of RNA was reverse-transcribed using a 
High Capacity Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA).  
Real-time PCR was performed using Taqman Gene Expression Assays and Taqman Fast 
Universal Mastermix (Applied Biosystems).  Gene expression was quantified using the 
standard curve method and ribosomal 18S was the endogenous control.  RNA was 
collected from 3 separate wells for each treatment group and expression of HO-1, GCLC, 
NQO1, catalase, Prdx3, and Prdx5 were assessed.    
Western Blotting 
Cells were collected in RIPA lysis buffer, sonicated and centrifuged, and 
supernatant was analyzed for protein concentration using the BCA assay.  Proteins were 
resolved on NuPage 4-12% bis-tris gels (Invitrogen) under denatured and reduced 
conditions, and transferred to a polyvinylidene membrane.  Membranes were blocked for 
1 hour using 5% (w/v) fat-free milk in Tris-buffered saline solution with 0.05% (v/v) 
Tween-20 (TBS-T).  Membranes were then probed overnight with primary antibody 
dissolved in 5% (w/v) bovine serum albumin in TBS-T.  Primary antibodies for 
antioxidant response proteins included HO-1 (Millipore, Temecula, CA, USA), GCLC 
(Abcam, Cambridge, MA, USA), and catalase (Abcam).  Nrf2 antibody was purchased 
from R&D systems (Minneapolis, MN, USA); and Nrf2 (H300) was purchased from 
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Santa Cruz (Santa Cruz, CA, USA).  β-actin (Sigma) or GAPDH (Santa Cruz) were used 
as the loading control.  For fractionated proteins (see below), nucleoporin (BD 
Biosciences) was used for nuclear fraction control and GAPDH was used as the cytosolic 
control.  The following day membranes were washed in TBS-T and probed with 
secondary antibody conjugated to horseradish peroxidase dissolved in 5% milk/TBS-T.  
HRP-conjugated secondary antibodies were donkey anti-mouse (Santa Cruz), rabbit anti-
goat (Santa Cruz) and goat anti-rabbit (Cell Signaling, Danvers, MD, USA).  
Recombinant Nrf2 (Abnova, Taipei, Taiwan) was used as a positive control for the anti-
Nrf2 antibody.  Signal was detected with Western Lightning Chemiluminescence 
Reagent Plus kit (PerkinElmer, Waltham, MA, USA). 
Protein Fractionation 
To analyze nuclear accumulation of Nrf2, cell protein lysates were fractionated 
into cytosolic and nuclear compartments using NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Fisher Scientific) per manufacturer’s instructions.  Briefly, 
cells from 6 wells were trypsinized with 0.2% trypsin, pooled, and centrifuged at 500 × g 
for 5 minutes and the pellet was washed with PBS.  Cell pellets were lysed and 
fractionated according to instructions for a 20 µL packed cell volume.  Samples were 
stored in -80°C freezer.   
Antioxidant Assay 
To measure antioxidant capacity, cells lysates were analyzed using a 
commercially available, colorimetric antioxidant assay (Sigma).  Three wells of cells per 
treatment group were collected in 1 mL of cold 1X assay buffer and pooled in 
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microcentrifuge tubes.  Lysates were sonicated and centrifuged at 12000 x g for 15 
minutes at 4 °C.  Assay was performed on supernatants in duplicate as directed.  Means 
were generated from 3 separate samples of each.   
Glutathione Assay Kit 
Total glutathione was measured using a Glutathione Assay Kit (Cayman 
Chemical, Ann Arbor, MI, USA).  Three wells of cells per treatment were collected in 
cold 50 mM phosphate buffer containing 1 mM EDTA and pooled.  Lysates were 
sonicated and centrifuged at 10,000 x g for 15 minutes at 4 °C and deproteinated with 
10% (w/v) metaphosphoric acid.  Assay was performed in duplicate as directed.  Means 
were generated from 3 separate samples of each.  Samples were normalized to milligrams 
of protein.   
Study Design 
Preliminary Study.  A preliminary study was performed to determine the 
developmental period in which fetal rat calvarial cells were most responsive to oxidative 
stress.  Cells were treated with 0-300 µM hydrogen peroxide, a common inducer of 
oxidative stress, starting at confluence (D5).  Treatment was continued either throughout 
differentiation (D5-21), during early differentiation only (D5-13), or during late 
differentiation only (D13-21).  Alkaline phosphatase staining, along with RNA collection 
for real-time PCR analysis of osteoblast phenotype markers, was performed over a time 
course throughout differentiation starting at D5.  At D21 alkaline phosphatase stained 
cultures were co-stained with von Kossa technique.  These studies determined the time 
points evaluated in quercetin studies described below.   
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Quercetin Studies.  To assess the effects of quercetin metabolites on the acute 
antioxidant response, cells were treated starting at D5 with 3 different quercetin 
metabolites at doses up to 20 µM for a total of 48h.  Alternatively, some cells received a 
mixture of all 3 metabolites simultaneously (2:1:1 mixture, 10 µM Q3G: 5 µM ISO: 5 
µM QRC).  Samples were collected along a time course (0 to 48h) and antioxidant 
response genes and proteins and cell signaling proteins were analyzed as described 
above.  As a positive control, some cells were treated with tBHQ, a known inducer of the 
antioxidant response, at doses of 0, 20, or 40 µM for 3, 6, or 12 hours. 
Statistics 
Data are expressed as mean +/- SEM.  Statistical differences were determined 
using one-way analysis of variance (ANOVA) with Tukey post hoc analysis (SPSS 
version 17.0 for Windows, Chicago, IL, USA).  Univariate analysis was performed to 
check for interactions when there were two main effects of dose and time.  Student’s t-
tests were performed between control and treatment groups within each day when main 
effects were significant.  The α level was set at 0.05. 
Results 
Preliminary Study 
Figure 2 shows representative wells co-stained for alkaline phosphatase and von 
Kossa (2A) and the quantification of mineralized nodules (2B) after treatment with 0-300 
µM hydrogen peroxide throughout differentiation (D5-21), or during early (D5-13) or 
late differentiation only (D13-21).  Cells treated with hydrogen peroxide throughout 
differentiation exhibited dose-dependent suppression of alkaline phosphatase staining, 
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and the number of mineralized nodules was approximately 40% (p < 0.05) and 50% (p < 
0.05), in wells treated with 150 µM and 300 µM hydrogen peroxide, respectively.  There 
were 50% fewer mineralized nodules (p < 0.05) in cells treated with 300 µM hydrogen 
peroxide during early differentiation only, while in contrast, cells treated only during late 
differentiation were similar to 0 µM control.  Since hydrogen peroxide produced robust, 
sustained effects on osteoblast phenotypic development after treatment during early 
differentiation only, the main subsequent quercetin studies focused on treatment effects 
during this early differentiation period only.   
Quercetin Metabolites Up-regulate Antioxidant Genes and Proteins 
Treating cells up to 48h with 20 µM QRC resulted in marked up-regulation in 
expression of several genes involved in the antioxidant response, including HO-1, GCLC, 
and catalase (Figure 3A).  HO-1 and GCLC were significantly (p < 0.05) up-regulated as 
early as 3h after beginning 20 µM QRC treatment compared to 0 µM control, and up-
regulation was sustained for all time points for the entire 48h period.  In contrast, catalase 
gene expression was not markedly altered until 12h after treatment and up-regulation was 
sustained at 24 and 48h.  Alterations in gene expression levels of NQO-1 and Prdx 3 were 
not detected, and levels of Prdx 5 were only slightly up-regulated by QRC and only at 24 
and 48h.  Protein levels of HO-1 and GCLC were up-regulated similarly to gene 
expression (Figure 3B), but catalase protein expression was not, and appeared to be 
down-regulated after 24 and 48h after 20 µM QRC treatment compared to control (0uM). 
Gene and protein expression of HO-1, GCLC, and catalase were also analyzed after 
treatment with either ISO, a methylated metabolite, Q3G, a glucuronidated metabolite 
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(Figure 4), or a 2:1:1 mixture of all three metabolites (10 µM Q3G, 5 µM QRC, and 5 
µM ISO) (Figure 5).  The Prdx 3 and 5, and NQO-1 were not analyzed since mRNA and 
protein levels were not altered by QRC at any time point.  Treating cells with a 20 µM 
dose of ISO up-regulated levels of HO-1 and GCLC at both the mRNA (Figure 4A) and 
protein levels (Figure 4B), but these effects were less robust compared to the effects of 
QRC.  There were no major alterations in catalase expression after treating with ISO.  
There was no marked up-regulation of HO-1, GCLC, or catalase after treatment with 
Q3G at the mRNA (Figure 4C) or protein level (Figure 4D).  The metabolite mixture 
resulted in up-regulation of HO-1 and GCLC at the mRNA and protein level (Figure 5), 
but there did not appear to be an additive, synergistic effect, such that the combination of 
metabolites resulted in more robust up-regulation compared to QRC alone.   
Quercetin Aglycone did not Alter Levels of Nrf2 
Since 20 µM QRC robustly up-regulated the expression of three Nrf2 target genes 
(HO-1, GCLC, and catalase), protein levels of transcription factor Nrf2 were assessed.  
The Nrf2 antibody detected two doublets that migrated to about 100 kDa and 70 kDa.  It 
has been shown that endogenous Nrf2 does not migrate to its predicted molecular weight 
during electrophoresis, and the 95-100 kDa band is thought to be the biologically active 
relevant Nrf2 (Lau et at al 2013, Pi et al).  Cells treated with 20 µM QRC did not show 
any alterations in Nrf2 protein expression at any time point up to 48h after treatment 
(Figure 6).  To further address whether Nrf2 accumulated in the nucleus, Western blots 
were performed on nuclear protein fractions at doses up to 60 µM for up to 12h.  Data 
show that Nrf2 accumulation was not observed in the nucleus or the cytoplasm in any 
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pattern that corresponded to QRC treatment (Figure 7).   Similarly, treatment of cells with 
tert-butylhydroquinone did not result in the up-regulation of Nrf2 at any time point in 
spite of dose-dependent up-regulation of HO-1 after 6 and 12h of treatment (data not 
shown).     
Quercetin Altered Levels of Phosphorylated ERK1/2 and NFκB 
Since ERK1/2 has been shown to be involved in stress signaling and quercetin-
induced responses in other cell types, phosphorylated and total ERK1/2 protein levels 
were assessed by Western blotting.  A 20 µM dose of QRC down-regulated levels of 
phosphorylated ERK1/2 within 1.5h of treatment below basal levels, and was sustained 
through 6 h after treatment (Figure 8a).  Similarly, total levels of NFκB were down-
regulated at each of the time points analyzed (Figure 8b).  
Quercetin did not Alter Antioxidant Capacity or Glutathione Levels  
Since QRC up-regulated expression of antioxidant response genes and proteins, 
the total antioxidant capacity of the cells was measured to determine if this protein up-
regulation resulted in concomitant changes in the antioxidant status of the cell.  The 
overall antioxidant capacity of the cells was not significantly altered by QRC treatment at 
any of the time points analyzed (p > 0.05) (Figure 9A).  GCLC is the rate-limiting 
enzyme in the synthesis of glutathione, a major cellular detoxifying thiol, and since 
GCLC was up-regulated by 20 µM QRC, total glutathione levels were also assessed.  
Total glutathione levels were not significantly altered by quercetin treatment at any of the 
time points analyzed (p > 0.05) (Figure 9B).   
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Discussion and Conclusions 
These studies provide novel observations of the osteoblast antioxidant response 
after stimulation with quercetin metabolites.  The 20 µM dose of two quercetin 
metabolites, QRC and ISO, markedly up-regulated the expression of three antioxidant 
genes (HO-1, GCLC, and catalase) in primary osteoblasts, with QRC producing the most 
robust effect.  Up-regulation of HO-1 and GCLC mRNA resulted in congruent up-
regulation in protein levels, but catalase proteins were not congruently altered with 
mRNA, suggesting that other mechanisms are involved in regulating the final level of 
catalase protein in osteoblasts.  The similar patterns of up-regulation of antioxidant gene 
expression after treatment with both QRC and ISO suggest that these two metabolites 
may stimulate similar pathways to induce the antioxidant response, but that conjugation 
of the aglycone molecule diminishes this stimulatory effect, possibly due to alterations in 
the permeability of the cells due to the conjugation of the metabolites.  This theory is 
supported by results from cells treated with the mixture of metabolites, where the up-
regulation of gene expression appeared to be consistent with the presence of the 5 µM 
dose of QRC in the mixture, and did not result in detectable additive effects due to the 
presence of the other two metabolites (Figure 5).  In contrast to ISO and QRC, Q3G did 
not up-regulate expression of any antioxidant genes and proteins.  This observation is in-
line with in vitro studies in neurons, and may be due to the relatively large size of the 
glucuronic acid conjugate, which would prevent it from entering the cell [20].   
Not all antioxidant response genes assessed in this study were up-regulated by 
quercetin metabolites, including Prdx3, Prdx5, and NQO1.  These data suggests that 
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quercetin metabolites do not produce a global effect on the expression of all antioxidant 
genes, rather there appear to be mechanisms in place to regulate the specificity the genes 
that are transcribed.  Based on this study, osteoblasts exposed to quercetin metabolites 
during early differentiation activate pathways that up-regulate expression of HO-1 and 
GCLC genes and proteins, and the functional outcome of the quercetin-induced up-
regulation of the osteoblast antioxidant response may therefore rely on the activities of 
these two proteins.    
These data are generally consistent with studies in other cell types that show up-
regulation of antioxidant gene expression, however, unlike other studies, this did not 
appear to coincide with detectable accumulation of Nrf2 protein, even at doses 2 to 3 
times higher than that used to stimulate transcription of Nrf2 target genes (HO-1 and 
GCLC).  The absence of Nrf2 accumulation was also observed in this study after 
treatment with tBHQ, a well-known inducer of Nrf2 accumulation and activation [21].  It 
is not clear why Nrf2 accumulation was not detected alongside up-regulation of 
antioxidant genes.  The control of Nrf2 activation and subsequent transcription of 
antioxidant genes is complex and involves multiple post-translational modifications of 
both Nrf2 and its cytoplasmic sequestering protein, Keap 1, including phosphorylation, 
alterations in redox sensitive cysteine residues, and dimerization of Nrf2 with nuclear 
proteins [8].  These post-translational mechanisms appear to be differentially altered 
depending on the stimulus and the cell type, and result in variability in the level of Nrf2 
accumulation and kinetics of the Nrf2-mediated transcription [21, 22, 23].  Further 
experiments to examine Nrf2 post-translational modifications and Nrf2 activity levels in 
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osteoblasts are needed before the role of Nrf2 in the quercetin-induced up-regulation of 
the antioxidant response can be ruled out.     
Unlike Nrf2, these data clearly showed suppression of phosphorylated ERK1/2 
and NFκB, which suggests a role for these cell signaling proteins in initiating or 
sustaining quercetin-induced up-regulation of the osteoblast antioxidant response.   There 
are currently only two studies examining the effect of quercetin aglycone on ERK 
signaling pathways in osteoblast cell lines.  In MC3T3-L1 osteoblasts quercetin induced 
phosphorylation of ERK1/2 up to 6h after treatment with 20 µM quercetin [24], and in 
MG-63 osteosarcoma cells [25], 50 µM quercetin induced a transient phosphorylation of 
ERK1/2 after only 5 minutes.  Both of these studies are in direct contrast to the effects 
that were observed using primary cultures isolated from fetal rat calvaria.  In other cell 
types, alterations in ERK1/2 phosphorylation by quercetin aglycone have been described, 
but results are inconsistent despite similar doses (20-30uM) and time points (up to 24h) 
among studies.  For example, quercetin suppressed phosphorylated ERK1/2 in primary 
cortical neurons [26], but up-regulated phosphorylated ERK1/2 in BEAS-2B bronchial 
epithelial cells [27].   
Like ERK1/2, quercetin appears to suppress NFκB protein levels.  Several lines of 
evidence suggest that Nrf2 activators down-regulate NFκB signaling [28], and this has 
also been shown in MC3T3-E1 osteoblasts [29], which suggests that activation of the 
antioxidant response may also be anti-inflammatory.  This finding is of particular 
importance to bone, since inflammation has been shown to down-regulate development 
of the osteoblast phenotype and activate osteoclastic resorption.  The effect of quercetin 
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on cell signaling pathways is markedly different depending on cell type and culture 
conditions.  Future studies are needed to establish the exact role of ERK1/2 and NFκB in 
the osteoblast stress response, and to what extent these signaling pathways are required 
for up-regulation of antioxidant genes.   
Because of the up-regulation of HO-1 and GCLC proteins, the overall antioxidant 
capacity and total glutathione levels were expected to be higher in QRC-treated cells, 
however, we did not detect alterations in either of these parameters at any time point.  
This indicates that QRC did not significantly alter levels of electron-accepting thiols or 
other endogenous free radical scavengers.  Similarly, other studies using comparable 
doses of QRC have shown that an up-regulation of GCLC [11, 30], is not necessarily 
followed by increased levels of total glutathione [11].  Quercetin is thought to form 
glutathione adducts [20] suggesting that the up-regulation of GCLC may be a 
compensatory mechanism to keep glutathione at steady-state levels, which may explain 
why we did not see a concomitant rise in both GCLC and levels of total glutathione.   The 
induction of HO-1 is commonly seen as part of the antioxidant response and presumably 
results in increased catabolism of heme into Fe2+, biliverdin, and CO.  Some lines of 
evidence show that these metabolic products have free radical scavenging ability, but 
may also have direct effects on cytoprotective cell signaling pathways [31].  Taken 
alongside the data from the current study, it appears that the functional outcome of HO-1 
and GCLC up-regulation is more complex than an overall increase in cellular free radical 
scavenging capabilities.  It may also be possible that osteoblasts in these culture 
conditions already have a relatively high antioxidant capacity that was not altered to 
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detectable levels by the relatively low dose of QRC.  Since the overall functional 
outcome of HO-1 and GCLC up-regulation remain unclear, further studies are needed to 
assess alterations in specific steps involved in glutathione regulation and heme 
catabolism.   
The quercetin-induced antioxidant response in fetal rat calvaria cells occurred in 
early stages of differentiation (D5-D7), which was the same time that hydrogen peroxide 
induced marked suppression of phenotype as determined in the preliminary study.  
Therefore, osteoprogenitors and pre-osteoblasts in oxidative stress environments may 
benefit from stimulation with antioxidants that offer potentially protective effects on 
osteoblast phenotypic development.  Although this study demonstrates that plasma 
metabolites of quercetin stimulate the osteoblast antioxidant response, inherent 
difficulties in translating the in vitro setting to physiological conditions limits the 
interpretation of data in an in vivo context.  The doses required to detect effects in this 
study are generally considered higher than that found in the blood plasma after quercetin 
consumption [32,33], and high inter-individual variability has been described among 
human study participants that consume quercetin-rich foods [34].  Additionally, roughly 
20 plasma quercetin metabolites have been reported after consuming quercetin or 
quercetin-rich foods [32], but we are only aware of three metabolites that are 
commercially available.  Nevertheless, these data offers important insights into the 
overall effect of flavonoids on osteoblast biology and also provides potential pathways to 
investigate in future studies examining the osteoblast antioxidant response and the role of 
oxidative stress in osteoporosis. 
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Figure Legends 
Figure 3.1.  Quercetin metabolites.  A) Quercetin aglycone, B) methylated metabolite, 
isorhamnetin, C) and glucuronidated metabolite, quercetin-3-O-glucuronide.   
Figure 3.2. Osteoblast-like phenotype development in colonies isolated from fetal rat 
calvaria after treatment with 0, 75, 150, or 300 µM hydrogen peroxide.  A) 
Representative wells of alkaline phosphatase (pink) and von Kossa (black) co-stained 
colonies after treatment with 0-300 µM hydrogen peroxide continuously (D5-21), or 
during early (D5-13) or late (D13-21) differentiation only.  B) Number of mineralized 
nodules present at D21 after treatment with 0-300 µM hydrogen peroxide, expressed as a 
percentage of 0uM control; Means +/- SEM, n=6 independent wells of RNA from the 
same experiment.  Significance (p < 0.05) was assessed by one-way analysis of variance.  
Means that do not share a common letter are significantly different.  Similar results were 
observed in at least 2 independent studies. 
Figure 3.3.  Expression of antioxidant response genes and proteins in osteoblast-like 
colonies after treatment with 20 µM quercetin aglycone up to 48h starting at confluence 
(day 5).  A) Real-time PCR amplification of heme oxygenase-1 (HO-1), γ-glutamyl-
cysteine ligase catalytic subunit (GCLC) and catalase after up to 48h of treatment with 
quercetin aglycone.  Means +/- SEM, n= 3 separate wells of RNA from the same 
experiment.  Univariate analysis of PCR revealed a significant interaction between time 
and quercetin treatment (p < 0.05).  Significance between quercetin and vehicle control 
was assessed by student’s t-tests within each time point.  Asterisks indicate significant 
difference (p < 0.05) compared to control within each time point.  B) Protein levels of 
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HO-1, GCLC, and catalase as assessed by Western blotting after up to 48h treatment with 
quercetin.  Similar results were observed in 3 independent studies. 
Figure 3.4.  Expression of antioxidant response genes and proteins in osteoblast-like 
colonies after treatment with 20 µM isorhamnetin, or 20 µM quercetin-3-O-glucuronide 
for up to 48h starting at confluence (day 5).  Real-time PCR amplification of heme 
oxygenase-1 (HO-1), γ-glutamyl-cysteine ligase catalytic subunit (GCLC) and catalase 
after up to 48h of treatment with A) isorhamnetin or C) quercetin-3-O-glucuronide.  
Means +/- SEM, n=3 independent wells of RNA from the same experiment.  Western 
blotting of heme oxygenase-1 (HO-1), γ-glutamyl-cysteine ligase catalytic subunit 
(GCLC) and catalase after up to 48h of treatment with B) isorhamnetin and D) quercetin-
3-O-glucuronide.  Univariate analysis of PCR revealed no interaction (p >0.05) between 
time and quercetin metabolite treatment.  Significance between quercetin and vehicle 
control was assessed by Student’s t-tests within each time point.  Similar results were 
observed in at least 2 independent studies.   
Figure 3.5.  Expression of antioxidant response genes and proteins in osteoblast-like 
colonies after treatment with a 2:1:1 mixture of 10 µM quercetin-3-O-glucuronide, 5 µM 
isorhamnetin, and 5 µM quercetin aglycone up to 48h starting at confluence (day 5).  A) 
Real-time PCR amplification and B) Western blotting analysis of heme oxygenase-1 
(HO-1), γ-glutamyl-cysteine ligase catalytic subunit (GCLC) and catalase after up to 48h 
of treatment with a 2:1:1 mixture quercetin metabolites.  For PCR, means +/- SEM, n=3 
independent wells of RNA from the same experiment.  Univariate analysis revealed no 
interaction (p > 0.05) between time and quercetin treatment for catalase and GCLC.  
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Univariate analysis of HO-1 revealed a significant interaction.  Significance between 
quercetin and vehicle control was assessed by Student’s t-tests within each time point.  
Asterisks indicate significant difference (p < 0.05) compared to control within each time 
point.  Similar results were observed in at least 2 independent studies.   
Figure 3.6.  Western blot of Nrf2 protein expression in whole lysates of osteoblast-like 
cells after treatment with 0 to 60 µM quercetin aglycone for up to 48h starting at 
confluence (day 5).   
Figure 3.7.  Western blot of Nrf2 protein expression in nuclear fractions of osteoblast-
like cells after treatment with up to 60 µM quercetin for up to 12h starting at confluence 
(day 5).   
Figure 3.8.  Western blots of ERK1/2 and NFkB after acute treatment with 20 µM 
quercetin aglycone.  A) Western blot of ERK1/2 and phosphorylated ERK1/2 after 
treatment with 20 µM quercetin aglycone up to 24h starting at confluence (D5); B) 
Western blot of NFκB after treatment with 20 µM quercetin aglycone up to 48h starting 
at confluence (D5).  
Figure 3.9.  A) Antioxidant capacity and B) total glutathione levels of cell lysates after 
treatment with 20 µM quercetin aglycone for up to 12h.  Means +/- SEM, n=3 separate 
samples from the same experiment (3 wells pooled per sample).  Univariate analysis 
revealed no interaction (p > 0.05) between time and quercetin treatment for either assay.  
Significance between quercetin and vehicle control was assessed by student’s t-tests 
within each time point.  Similar results were observed in 2 independent studies.   
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Figures 
 
 
Figure 3.1.  Quercetin metabolites.  A) Quercetin aglycone, B) methylated metabolite, 
isorhamnetin, C) and glucuronidated metabolite, quercetin-3-O-glucuronide. 
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Figure 3.2.  Osteoblast-like phenotype development in colonies isolated from fetal rat 
calvaria after treatment with 0, 75, 150, or 300 µM hydrogen peroxide.  A) 
Representative wells of alkaline phosphatase (pink) and von Kossa (black) co-stained 
colonies after treatment with 0-300 µM hydrogen peroxide continuously (D5-21), or 
during early (D5-13) or late (D13-21) differentiation only.  
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Figure 3.3.  Expression of antioxidant response genes and proteins in osteoblast-like 
colonies after treatment with 20 µM quercetin aglycone up to 48h starting at confluence 
(day 5).  A) Real-time PCR amplification of heme oxygenase-1 (HO-1), γ-glutamyl-
cysteine ligase catalytic subunit (GCLC) and catalase after up to 48h of treatment with 
quercetin aglycone. 
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Figure 3.4.  Expression of antioxidant response genes and proteins in osteoblast-like 
colonies after treatment with 20 µM isorhamnetin, or 20 µM quercetin-3-O-glucuronide 
for up to 48h starting at confluence (day 5) 
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Figure 3.5.  Expression of antioxidant response genes and proteins in osteoblast-like 
colonies after treatment with a 2:1:1 mixture of 10 µM quercetin-3-O-glucuronide, 5 µM 
isorhamnetin, and 5 µM quercetin aglycone up to 48h starting at confluence (day 5).   
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Figure 3.6.  Western blot of Nrf2 protein expression in whole lysates of osteoblast-like 
cells after treatment with 0 to 60 µM quercetin aglycone for up to 48h starting at 
confluence (day 5). 
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Figure 3.7.  Western blot of Nrf2 protein expression in nuclear fractions of osteoblast-like 
cells after treatment with up to 60 µM quercetin for up to 12h starting at confluence (day 
5). 
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Figure 3.8.  Western blots of ERK1/2 and NFkB after acute treatment with 20 µM 
quercetin aglycone.  A) Western blot of ERK1/2 and phosphorylated ERK1/2 after 
treatment with 20 µM quercetin aglycone up to 24h starting at confluence (D5); B) 
Western blot of NFκB after treatment with 20 µM quercetin aglycone up to 48h starting 
at confluence (D5).  
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Figure 3.9.  A) Antioxidant capacity and B) total glutathione levels of cell lysates after 
treatment with 20 µM quercetin aglycone for up to 12h. 
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CHAPTER IV 
 
QUERCETIN PARTIALLY PRESERVES DEVELOPMENT OF THE OSTEOBLAST 
PHENOTYPE IN FETAL RAT CALVARIAL CELLS IN AN  
OXIDATIVE STRESS ENVIRONMENT 
 
 
Abstract 
 
Oxidative stress has been linked to development of osteoporosis, which may be 
due, in part to suppression of osteoblast differentiation.  Because of the link between 
oxidative stress and osteoblast phenotypic development, targeting the osteoblast 
antioxidant response may alleviate oxidative stress and support bone health.  Quercetin is 
a common dietary flavonol that up-regulates expression of antioxidant response gene and 
proteins, heme oxygenase-1 (HO-1) and γ-glutamate cysteine ligase catalytic subunit 
(GCLC), after acute treatment (up to 12h) during early differentiation, starting on day (D) 
5 (confluence).  The overall purpose of this study was to characterize the effect of 
quercetin aglycone (QRC) on the osteoblast antioxidant response and phenotypic 
development in fetal rat calvarial osteoblasts cultured in an oxidative stress environment.  
The first aim was to assess the extent that QRC blocked hydrogen peroxide induced 
suppression of the osteoblast phenotype.  Cells treated for 4-days (D5-9) with up to 300 
µM hydrogen peroxide had lower levels of alkaline phosphatase staining, altered cell 
morphology, and significantly lower expression levels of osteoblast phenotypic gene 
markers (p < 0.05), but suppression of these parameters was partially blocked by a 12h 
pretreatment with 20 µM QRC.  The second aim was to characterize alterations in the 
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osteoblast antioxidant response when cells were cultured with hydrogen peroxide with or 
without QRC pretreatment.   Hydrogen peroxide (300 µM) treatment produced a 
sustained up-regulation of HO-1 protein expression within 3h after beginning treatment 
that was also evident at the end of the 4-day incubation period.  In cells pretreated with 
20 µM QRC, however, expression levels of HO-1 were suppressed.    Hydrogen peroxide 
also blocked QRC-induced up-regulation of GCLC.  These results suggest that an acute 
12h pretreatment with QRC “primes” cells for a subsequent exposure to hydrogen 
peroxide, which blocks the hydrogen peroxide-induced activation of the antioxidant 
response and prevents hydrogen peroxide-induced suppression allowing cells to proceed 
with differentiation programs.   
Introduction 
Oxidative stress contributes to the development of osteoporosis, in part, by 
directly suppressing the number and function of bone-forming osteoblasts.  This finding 
underscores the importance of understanding the osteoblast antioxidant stress response, 
and suggests that alleviating oxidative stress in osteoblasts may be a promising strategy 
for preventing osteoporosis.  Quercetin (QRC) is an antioxidant flavonoid found 
abundantly in plant-based foods and supplements, and is a target molecule for research 
investigating the therapeutic potential of antioxidants in chronic diseases linked to 
oxidative stress [1].  Several studies in rodent models of estrogen deficient bone loss 
demonstrate that consumption of QRC or QRC-rich foods results in higher bone density 
[2], improved microarchitecture [3,4], and higher bone strength [3] compared to estrogen 
deficient rodents that did not consume QRC.  Furthermore, it has been shown that bone 
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loss from both aging [5] and estrogen deficiency [6] is partly attributed to oxidative stress 
in osteoblasts.  Taken together these studies suggest that antioxidants may preserve the 
differentiation and function of osteoblasts if cells are in an oxidative stress environment.   
Current studies investigating the specific effects of QRC on osteoblasts are 
limited and contradictory.  Studies show stimulation of alkaline phosphatase activity [7] 
in MC3T3-E1 cells, and up-regulated osteoblast phenotypic gene markers and calcium 
deposition in multipotent primary cells isolated from adipose tissue [8], but other studies 
show that QRC stimulates apoptotic cell death of MC3T3-E1 cells [9].  Additionally, 10 
µM QRC aglycone enhanced TNFα-induced apoptotic cell death in MC3T3-E1 
osteoblast cell lines, but not in primary calvarial cultures [10].  The pro-apoptotic effects 
of QRC on osteoblasts are not congruent with animal studies that show a protective effect 
of QRC on bone health.  These results are likely due, in part, to variability in cell types 
and culture conditions, but also suggest that QRC may have hormetic effects, such that 
low doses or short duration of treatment produce a protective antioxidant response, where 
higher doses or chronic exposure results in damaging pro-oxidant effects.   
In other cell types, the presence of pro-oxidants or electrophiles induces the 
antioxidant response, which classically involves activation of the transcription factor, 
Nrf2, which binds to antioxidant response elements in the promoter region of genes 
coding for proteins that function to maintain redox homeostasis [11].  Previously, we 
have shown that QRC induces expression of Nrf2-target genes heme oxygenase-1 (HO-1) 
and γ-glutamate cysteine ligase catalytic subunit (GCLC) in osteoblast cultures isolated 
from fetal rat calvaria.  These alterations were accompanied by down-regulation in 
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phosphorylated ERK1/2, but not in total protein levels of Nrf2.  Activation of these genes 
suggests that QRC acts as a pro-oxidant in these cell cultures.  However, since these 
genes are considered “protective,” we hypothesized that a short duration of QRC at a 
relatively low dose would prevent damaging effects of a subsequent oxidative event and 
preserve development of osteoblast phenotype.  Because of the link between oxidative 
stress and phenotypic development of osteoblasts, we also hypothesized that any 
protective event would coincide with osteoblast antioxidant response pathways.  To our 
knowledge there have been no studies specifically examining the effect of QRC on the 
antioxidant response and phenotypic development in primary osteoblasts when cells are 
cultured in a suppressive, oxidative stress environment.     
This study had two aims.  The first specific aim was to examine the extent to 
which alterations in the antioxidant response altered development of the osteoblast 
phenotype.  To address the first aim osteoblasts were pretreated for 12h with QRC to 
stimulate the antioxidant response, followed by treatment with hydrogen peroxide, a 
commonly used inducer of oxidative stress in vitro, to suppress osteoblast phenotype 
[12,13].  Osteoblast phenotype was assessed by measuring alkaline phosphatase staining 
and expression of osteoblast phenotypic gene markers.  We hypothesized that 
pretreatment with QRC would preserve osteoblast phenotype when cells were cultured 
with hydrogen peroxide.  The second specific aim was to characterize alterations in the 
osteoblast antioxidant response when cells were cultured in an oxidative stress 
environment.  To address the second specific aim, cells were pre-treated for 12h with 
QRC, which was followed by hydrogen peroxide treatment, and the osteoblast 
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antioxidant response was assessed by measuring expression levels of two antioxidant 
genes and proteins that are known to be up-regulated by QRC in fetal rat calvaria 
cultures, and ERK1/2 and Nrf2 proteins that are potentially involved in the quercetin-and 
hydrogen peroxide-mediated antioxidant response.  We hypothesized that QRC would 
alter the antioxidant response induced by hydrogen peroxide, and this would involve Nrf2 
and ERK1/2. 
Materials and Methods 
Reagents 
Alpha-modified minimal essential media, fetal bovine serum, gentamicin, 
fungizone, dimethylsulfoxide (DMSO), and silver nitrate were purchased from Thermo 
Fisher Scientific (Waltham, MA, USA).  Penicillin, collagenase, ascorbic acid, β-
glycerophosphate, dexamethasone, red violet LB salt, naphthol AS MX-PO4, hydrogen 
peroxide, tert-butylhydroquinone (tBHQ), QRC aglycone, and were purchased from 
Sigma (St. Louis, MO, USA).   
Animals and Diet 
Timed-pregnant Sprague-Dawley rats were obtained from Harlan on D4 of 
pregnancy and housed with a 12-hour light/dark cycle, and ad libitum access to water and 
soy protein-free rodent diet (Harlan, 2920X).  A soy-free diet was used to avoid potential 
confounding effects of isoflavones found in soy on osteoblast development in utero.  The 
total isoflavone concentrations, as measured by the manufacturer, were 3 and 8 mg/kg of 
diet for the batches used in these studies, and were near the level of detection.  Dams 
were euthanized on D21 of gestation by overexposure to CO2, and fetuses removed.  
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Fetuses were placed in a petri dish on ice to induce hypothermia before decapitation and 
removal of calvariae (frontal and parietal bones) for cell isolation.  All procedures were 
reviewed and approved by the University of North Carolina at Greensboro Institutional 
Animal Care and Use Committee.   
Cell Culture 
To obtain osteoblast-like cells, calvariae were minced and subjected to 5, serial 
incubations with collagenase to release cells from surrounding tissue.  Cells from the first 
incubation were discarded, while cells from the second through fifth digestions were 
plated each in separate T75 flasks.  The following day cells were trypsinized, pooled, and 
plated at 3000 cell/cm2 in 6-well culture dishes.  Cells were incubated at 37°C under 5% 
CO2 for the duration of the experiment.  Cell culture media was changed every 2-3 days 
and consisted of alpha-modified minimal essential media supplemented with 10% fetal 
bovine serum, 10% antibiotic solution (penicillin, gentamicin, and fungizone), 
supplemented with ascorbic acid (50 µg/µL), beta-glycerophosphate (10 mM), and 
dexamethasone (10-8 M) to induce osteogenesis.  Fetal rat calvarial cultures undergo 
distinct proliferation and differentiation phases.   After plating, cells proliferate until 
confluence (day 5), which is followed by a 2-week differentiation phase (days 5-21), 
culminating in formation of discrete bone-like nodules that stain positive for cell-surface 
protein alkaline phosphatase, and secrete a collagen-based protein matrix that becomes 
mineralized.  Alongside nodule formation, fetal rat calvaria exhibit temporal up-
regulation of genes that are characteristic of the osteoblast phenotype, including collagen 
type 1a (Coll1a), alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteocalcin 
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(OCN), as well as the master regulator of osteoblast differentiation, transcription factor 
Runx2 [14].   
Alkaline Phosphatase Staining 
This method has been previously described [15].  Briefly, cells were washed in 
PBS, fixed in 10% neutral formalin buffer for 15 minutes, and rinsed with deionized 
water.  Alkaline phosphatase-positive cells were stained using Naphthol AS MX-PO4 as 
substrate and Red Violet LB salt as coupler.  Colonies were examined microscopically 
under bright field illumination and micrographs were taken with an Olympus DP71 
digital camera.   
Preparation of Stock Solutions 
QRC was dissolved in degassed dimethylsulfoxide (DMSO), aliquoted, and stored 
at -20°C.  Hydrogen peroxide (30% w/v) was freshly diluted in sterile, deionized water 
just before use.  Quercetin at final concentration of 20 µM, and hydrogen peroxide at 
final concentrations of 150 or 300 µM were administered with fresh media.  The vehicle 
controls (0 µM) for hydrogen peroxide and QRC were sterile, deionized water and 0.1% 
(v/v) DMSO, respectively.   
Quantitative Real-time PCR 
Cells were lysed in 900 µL of Qiazol using a cell scraper and lysate was 
transferred to microcentrifuge tubes.  RNA was isolated using RNeasy Universal Minikit 
(Qiagen) per manufacturer’s instruction and quantified using a Nanodrop 
spectrophotometer.  Two micrograms of RNA was reverse-transcribed using a High 
Capacity Reverse Transcription kit (Applied Biosystems).  Real-time PCR was 
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performed using Taqman Gene Expression Assays and Taqman Fast Universal 
Mastermix (Applied Biosystems).  Gene expression was quantified using the standard 
curve method and ribosomal 18S as the endogenous control.  RNA was collected from at 
least 3 separate wells for each treatment group and used to assess antioxidant response 
genes HO-1, GCLC, or osteoblast phenotypic genes Runx2, Coll1a, ALP, BSP, and 
OCN.    
Western Blotting 
Cells were collected in RIPA lysis buffer supplemented with 10 mM sodium 
fluoride, 20 mM β-glycerophosphate, 0.1 mM sodium orthovanadate (Sigma), and 
protease inhibitor cocktail (Calbiochem).  Lysates were sonicated and centrifuged, and 
supernatant were analyzed for protein concentration using the BCA assay.  Proteins were 
resolved on NuPage 4-12% bis-tris gels (Invitrogen) under denatured and reduced 
conditions, and transferred to a polyvinylidene membrane.  Membranes were blocked for 
1 hour using 5% (w/v) fat-free milk in Tris-buffered saline solution with 0.05% (v/v) 
Tween-20 (TBS-T).  Membranes were then probed overnight with primary antibody 
dissolved in 5% (w/v) bovine serum albumin in TBS-T.  Primary antibodies for 
antioxidant response proteins included HO-1 (Millipore), GCLC (company).  Nrf2 
(H300) was purchased from Santa Cruz.  Phosphorylated and total ERK1/2 antibodies 
were purchased from Cell Signaling.  β-actin (Sigma) or GAPDH (Santa Cruz) were used 
as the loading control.  The following day membranes were washed in TBS-T and probed 
with secondary antibody conjugated to horseradish peroxidase dissolved in 5% 
milk/TBS-T.  HRP-conjugated secondary antibodies include donkey anti-mouse (Santa 
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Cruz) and goat anti-rabbit (Cell Signaling).  Signal was detected with Western Lightning 
Chemiluminescence Reagent Plus kit (PerkinElmer). 
Study Design 
Preliminary Study 1.   To determine the dose and duration of hydrogen peroxide 
treatment needed to suppress osteoblast phenotype to detectable levels, cells were treated 
with 0-300 µM hydrogen peroxide throughout early differentiation only (D5-13).   
Alkaline phosphatase staining was performed at several time points D5, D9, and D13.  
Additionally, RNA was collected on D9, and gene expression was analyzed with real-
time PCR.  Previous data showed that treating cells with 300 µM hydrogen peroxide 
during the first week of differentiation only (D5-13) produced lasting suppression of 
osteoblast phenotype that was observed at D21, even if cells were treated with control 
media (0 µM hydrogen peroxide) during the second week of differentiation (D13-21). 
Preliminary Study 2.  The assess the extent that an acute dose of QRC suppressed 
osteoblast phenotype, cells were treated with 0-40 µM QRC for 48h and alkaline 
phosphatase staining was performed to determine if osteoblast phenotypic development 
was altered by QRC alone.   
Quercetin Studies.  To assess the effects of QRC on the osteoblast phenotype and 
antioxidant response, cells were treated starting at confluence (D5) with 20 µM QRC for 
a total of 12h.  After the 12h pretreatment, cells received fresh media containing either 0 
or 300 µM hydrogen peroxide since the 300 µM dose consistently suppress osteoblast 
phenotype in preliminary studies.  Cell cultures received fresh media again on D7, 48h 
after treatment with hydrogen peroxide began, which contained either 0 or 300 µM 
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hydrogen peroxide.  The expression of antioxidant response genes and proteins, 
osteoblast phenotypic gene markers, and alkaline phosphatase staining was assessed after 
4 days (D5-9) of hydrogen peroxide to assess chronic or lasting effects of QRC.  
Additionally, antioxidant gene and protein expression was analyzed up to 24h after 
beginning hydrogen peroxide treatment to assess acute alterations   
Statistics 
Data are expressed as mean +/- SEM.  Statistical differences were determined 
using one-way analysis of variance (ANOVA) with Tukey post hoc analysis (SPSS Inc., 
version 17.0 for Windows, Chicago, IL, USA).  Univariate analysis was performed to 
check for interactions when there were two main effects of QRC treatment and hydrogen 
peroxide treatment.  For real-time PCR data, there was a significant interaction between 
the main effects of QRC pre-treatment and hydrogen peroxide for all oxidative stress 
genes (Figure 6A) and for ALP (Figure 4).  Student’s t-tests were performed between 0 
µM and 20 µM QRC within each dose of hydrogen peroxide.  The α level was set at 0.05.   
Results 
Preliminary Studies 
Hydrogen peroxide dose-dependently suppressed the number of alkaline 
phosphatase staining (Figure 1A) in fetal rat calvaria cultures when cells were treated 
starting at confluence (D5), and this effect was evident after only 4 days of treatment 
(D5-9).  Hydrogen peroxide also dose-dependently suppressed osteoblast phenotypic 
gene markers after 4 days of treatment (Figure 1B).  Therefore, a 4-day incubation with 
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300 µM hydrogen peroxide was used in subsequent studies to suppress osteoblast 
phenotype.   
Treating cells for 48h with up to 20 µM QRC did not markedly alter alkaline 
phosphatase staining, but staining was suppressed at the 40 µM dose (Figure 2).  
Therefore, subsequent studies used doses of 20 µM QRC to stimulate the antioxidant 
response.   
Quercetin Pretreatment Partially Preserves Osteoblast Phenotype 
Figure 3A shows representative wells of fetal rat calvarial cultures stained for 
alkaline phosphatase after 12h of QRC pre-treatment (0 or 20 µM) followed by 4 days of 
incubation with either 0 or 300 µM hydrogen peroxide.  Alkaline phosphatase staining 
was similar to control when cells were pretreated for 12h with QRC only, but cells treated 
with hydrogen peroxide for 4 days that were not first pretreated with QRC had fewer 
alkaline phosphatase positive colonies compared to controls.   In contrast, cells treated 
with hydrogen peroxide for 4 days after a 12h QRC pretreatment had more alkaline 
phosphatase positive colonies compared to hydrogen peroxide treated cells that were not 
pre-treated.   
Microscopic evaluation of stained wells revealed discrete foci of cuboidal cells 
that were intensely stained for alkaline phosphatase in both control wells, and in wells 
that were pre-treated with QRC without subsequent hydrogen peroxide treatment (Figure 
3B).  Hydrogen peroxide-treated cells that did not receive QRC pre-treatment were not 
organized into discrete colonies, cells retained a more fibroblastic morphology, and 
alkaline phosphatase staining was less intense compared to controls.  If cells were 
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pretreated with QRC before incubation with 300 µM hydrogen peroxide, colony 
formation, cell morphology, and alkaline phosphatase staining were similar to controls.   
Figure 4 shows the effect of QRC pretreatment and hydrogen peroxide on the 
expression of osteoblast phenotype gene expression.  Gene expression in cells pretreated 
with QRC and then changed to control media (0 µM hydrogen peroxide) was similar to 0 
µM control.  Hydrogen peroxide without QRC pretreatment suppressed Runx2, ALP, and 
BSP at the 300 µM dose.  There was also a marked dose-dependent suppression of OCN 
in cells treated with hydrogen peroxide without QRC pretreatment.  This hydrogen 
peroxide-induced suppression was mitigated if cells were first pre-treated with 20 µM 
QRC, particularly for OCN.  
Quercetin Pretreatment Blocks Induction of the Antioxidant Response by Hydrogen 
Peroxide  
 Figure 5 shows the effect of QRC pretreatment and hydrogen peroxide on the 
expression of antioxidant response genes (Figure 5A) and proteins (Figure 5B).   The 12h 
pretreatment with QRC did not result in detectable alterations in expression of GCLC 
genes or proteins after 4-days of incubation in media containing 0 µM hydrogen 
peroxide.  However, incubation for 4 days with a 300 µM dose of hydrogen peroxide in 
cells that were not pretreated with QRC resulted in slight up-regulation of GCLC mRNA 
and proteins, which was mitigated if cells were first pretreated with QRC.  A similar 
pattern was observed for HO-1 mRNA and protein expression.  Although HO-1 gene 
expression was statistically significant in cells that received QRC pretreatment alone, 
there were no marked alterations in this treatment group at the protein level when 
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compared to control.  Hydrogen peroxide treatment alone up-regulated HO-1 mRNA 
levels nearly 2-fold, but this up-regulation was mitigated by QRC pretreatment.   
 To examine the acute effect of QRC pretreatment and hydrogen peroxide 
alterations of the antioxidant response, HO-1 and GCLC proteins were assessed directly 
after QRC pretreatment and the first 24h of incubation with 0 or 300 µM hydrogen 
peroxide (Figure 6).  Treating cells for 12h with 20 µM QRC and then switching to 
control media (0 µM hydrogen peroxide) resulted in up-regulation of HO-1 and GCLC 
proteins compared to cells that were not pretreated (0 µM QRC).  Up-regulation was 
sustained up to 12h after QRC was removed and media switched to control conditions.  
Treating cells for 12h with 0 µM QRC and then switching to media containing 300 µM 
hydrogen peroxide robustly up-regulated HO-1 protein expression in cells after 3, 6, and 
12h.  This up-regulation was partially blocked, however, if cells were first pretreated with 
20 µM QRC, particularly at 6 and 12h.  Hydrogen peroxide treatment did not alter GCLC 
protein levels similarly to HO-1, since hydrogen peroxide appeared to block QRC-
induced up-regulation of GCLC proteins, such that levels were comparable to control at 
each time point.     
Nrf2 and ERK1/2 protein levels were also assessed in order to identify potential 
pathways involved in the QRC/hydrogen peroxide effects on osteoblast antioxidant 
response (Figure 7).  Nrf2 protein levels were not altered at any time point or any 
treatment condition.  At the end of the 12h pretreatment phosphorylated ERK1/2 was 
down-regulated in cells pretreated with 20 µM compared to 0 µM control.  If cells were 
switched to media containing 0 µM hydrogen peroxide, phosphorylated ERK1/2 was up-
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regulated after 1.5h, and returned to baseline levels within 3h in cells pretreated with 
0uM QRC, but up-regulation was sustained up to 3h in cells that were pre-treated with 20 
µM QRC.  If cells were pre-treated with 0 µM QRC followed by 300 µM hydrogen 
peroxide phosphorylated ERK1/2 was up-regulated and sustained up to 12h, while in 
cells pretreated with 20 µM QRC followed by 300 µM hydrogen peroxide, 
phosphorylated ERK1/2 was down-regulated after 1.5h and 3h. 
Discussion 
This study demonstrates a protective effect of the flavonol, QRC, on development 
of the osteoblast phenotype when cells are cultured in a suppressive, oxidative stress 
environment.   Hydrogen peroxide treatment for four days, starting at confluence, 
suppressed the number of alkaline phosphatase positive colonies and markedly altered 
cellular morphology.  Additionally, the most specific gene marker of osteoblasts, OCN, 
was robustly down-regulated by hydrogen peroxide, while less-specific gene markers 
expressed by immature osteoprogenitors (BSP, ALP, COLL1a, Runx2) were less robustly 
suppressed and only at the 300 µM dose.  This has also been shown in rabbit bone 
marrow stromal and calvarial osteoblasts, where a 4-day treatment with 100-200 µM 
hydrogen peroxide resulted in lower alkaline phosphatase staining, lower ALP activity, 
and fewer osteoblast-like colonies [12].  Together, these data indicate that 300 µM 
hydrogen peroxide prevents or delays progression of differentiation pathways that are 
necessary to produce mature osteoblasts in culture.  In contrast, cells pre-treated for 12h 
with 20 µM QRC before 300 µM hydrogen peroxide treatment, had more alkaline 
phosphatase staining, higher expression of osteoblast phenotypic gene markers, and cell 
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morphology that was more similar to vehicle controls (0 µM QRC treatment followed by 
0 µM hydrogen peroxide).      
There are several lines of evidence that suggest that hydrogen peroxide, or other 
oxidative stress conditions, suppress osteoblastic differentiation by diverting signaling 
proteins and energy resources away from pathways that promote osteogenic development 
and towards pathways that promote cell survival and redox homeostasis.  The Wnt/TCF 
signaling pathway is essential for osteoblast differentiation, but during oxidative stress, 
the FoxO transcription factors have been shown to directly compete for β-catenin, a 
protein required in both signaling pathways [16, 17], which results in down-regulating 
osteoblast differentiation.  Activation of the Nrf2-mediated antioxidant response has also 
been shown to block osteoblast differentiation by preventing recruitment of transcription 
factor Runx2 to the osteocalcin promoter [18].  Furthermore, calvarial cells isolated from 
Nrf2 knockout mice have higher expression levels of osteoblast phenotypic gene markers 
and mineralized surface area [19], suggesting that the antioxidant response is in direct 
competition with osteogenic signaling and transcription pathways.  Our data support the 
theory that osteoblast differentiation and antioxidant response pathways must be balanced 
for normal differentiation to occur.  This theory is demonstrated by the observation that 
QRC partially blocked hydrogen peroxide-induced expression of antioxidant response 
proteins, while simultaneously ameliorating hydrogen peroxide-induced suppression of 
the osteoblast phenotype.  This finding suggests that QRC pretreatment “primed” the 
cells for the subsequent oxidative insult, and that resources could be allocated towards 
normal differentiation and function, thus preserving phenotype.   
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Although both QRC and hydrogen peroxide altered levels of HO-1 and GCLC 
proteins, the acute, 20 µM dose of QRC did not suppress osteoblast phenotype, and 
protected cells from the suppressive effects of hydrogen peroxide.  Cells activate HO-1 
and GCLC gene transcription during oxidative stress, suggesting that QRC actually 
behaves as a pro-oxidant in these culture conditions, and only acts as an antioxidant 
relative to a subsequent oxidative stress event.  This observation is consistent with other 
studies that show harmful effects of QRC when used at higher doses or when co-treated 
simultaneously with an oxidative stress-producing reagent [10,20,21].  The acute, 
relatively low dose of QRC used in this study appears to produce a low grade antioxidant 
response that does not significantly block osteoblast differentiation, but primes cells for a 
subsequent oxidative insult.  The exact functional outcome of QRC-mediated alterations 
in HO-1 and GCLC remain unknown without further experiments, but it seems likely that 
QRC pre-treatment produces a cellular environment that is better equipped to scavenge 
free radicals, and may also inhibit the signaling pathways that mediate hydrogen 
peroxide-induced activation of the antioxidant response.   
Although QRC and hydrogen peroxide up-regulated two Nrf2 target genes, we did 
not detect accumulation of Nrf2 proteins in the cell lysates after treatment with either 
QRC or hydrogen peroxide.  The specific pathways involved in regulating Nrf2 
activation are complex and involve dimerization with other transcription factors, as well 
as post-translational modification of Nrf2 and its cytoplasmic sequestering protein, Keap 
1 [22], so further experiments are needed to completely rule out involvement of Nrf2.  
We did detect QRC induced alterations in phosphorylated ERK1/2 levels.  The 12h 
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pretreatment of QRC down-regulated phosphorylated ERK1/2, but levels were up-
regulated after changing to control media (0 µM hydrogen peroxide), and cells that 
received 20 µM QRC had sustained, higher levels of phosphorylated ERK1/2 up to 3h 
after the media change compared to cells that were pretreated with 0 µM QRC.  Cells that 
received 300 µM hydrogen peroxide also showed up-regulated levels of phosphorylated 
ERK1/2, but this up-regulation was transiently suppressed in cells pretreated with 20 µM 
QRC.  These data suggest that ERK1/2 signaling may be involved in the mechanism 
behind QRC’s protective effects.  ERK1/2 is indispensable for activating many 
transcription factors, and has been shown to be essential for osteoblast differentiation 
[23] but further investigation is needed in order to establish the exact role or requirement 
of ERK1/2 in these outcomes.   
These studies reinforce the idea that oxidative stress and activation of the 
antioxidant response is linked to suppression of the osteoblast phenotype.  Several studies 
in human populations have shown a positive association between flavonoid rich diets and 
bone density [24,25], and as previously mentioned, QRC is also protective of bone health 
in rodents.  Although it is unlikely that the dose of QRC used in this study is directly 
applicable to the in vivo bone environment, a role for plant-based dietary antioxidants in 
bone health cannot be ruled out.  In vitro, osteoblast differentiation progresses steadily 
throughout a 2 week period, but in vivo, bone formation in remodeling packets lasts for 
months, and occurs asynchronously at various places in the skeleton throughout life [26].  
Therefore, exposure to mixtures of dietary antioxidants in vivo after consuming flavonoid 
rich foods may result in cumulative positive effects on osteoblasts that difficult to detect 
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in the in vitro setting.  These studies provide insight into the antioxidant response of 
osteoblasts in the presence of oxidative stress and suggest that the osteoblast antioxidant 
pathway may be a viable target for intervention.  
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Figure Legends 
Figure 4.1.  Treatment during early differentiation (D5-9) with up to 300 µM hydrogen 
peroxide suppresses osteoblast phenotypic development.  (A) Representative wells of 
alkaline phosphatase stained cultures after treatment with hydrogen peroxide up to 300 
µM on D5, D9 and D13.  (B) Real-time PCR amplification of osteoblast phenotypic gene 
marker mRNA after treatment with up to 300 µM hydrogen peroxide from D5-D9 of 
culture.  Means +/- SEM, n= 3 separate wells of RNA from the same experiment.  
Significance between groups was assessed by one-way ANOVA with Tukey posthoc 
tests.  Means that do not share a common letter are significantly different (p < 0.05).   
Figure 4.2.  Acute treatment with 20 µM quercetin aglycone during early differentiation 
(D5-7) does not reduce alkaline phosphatase staining.  Representative wells of alkaline 
phosphatase stained cultures after treatment with up to 40 µM quercetin for 48h.   
Figure 4.3.  Pretreatment with 20 µM quercetin aglycone prevents hydrogen peroxide-
induced suppression of alkaline phosphatase staining and preserves normal cell 
morphology.  (A) Representative wells of alkaline phosphatase stained cultures after 
treatment with 0 or 20 µM quercetin for 12h followed by 4-day (D5-9) treatment with 
300 µM hydrogen peroxide.  (B) Colonies of osteoblast-like cells stained for alkaline 
phosphatase under 100X bright-field magnification.   Similar results were observed in 3 
independent studies.   
Figure 4.4.  Pretreatment with 20 µM quercetin aglycone partially blocks hydrogen 
peroxide-induced suppression of osteoblast phenotypic gene marker mRNA.  Real-time 
PCR amplification of osteoblast phenotypic gene marker mRNA after 12h pretreatment 
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with 0 or 20 µM quercetin aglycone followed by 4-day (D5-9) treatment with up to 300 
µM hydrogen peroxide.  Means +/- SEM, n= 3 separate wells of RNA from the same 
experiment.  Univariate analysis revealed no interaction (p > 0.05) between hydrogen 
peroxide and quercetin treatment for any gene except alkaline phosphatase (ALP).  
Significance between quercetin and vehicle control was assessed by student’s t-tests 
within each time point.  Similar results were observed in 2 independent studies.   
Figure 4.5. Pretreatment with 20 µM quercetin aglycone partially blocks up-regulation of 
HO-1 and GCLC mRNA and proteins after 4 days of hydrogen peroxide treatment. (A) 
Real-time PCR amplification of gene expression and (B) Western blotting of proteins of 
HO-1, GCLC and B-actin loading control after 12h pretreatment with 0 or 20 µM 
quercetin aglycone followed by 4-day (D5-9) treatment with up to 300 µM hydrogen 
peroxide.  Means +/- SEM, n= 3 separate wells of RNA from the same experiment.  
Univariate analysis revealed no interaction (p > 0.05) between hydrogen peroxide and 
quercetin treatment for either gene.  Significance between quercetin and vehicle control 
was assessed by student’s t-tests within each time point.  Similar results were observed in 
at least 2 independent studies.   
Figure 4.6. Pretreatment with 20 µM quercetin aglycone partially blocks hydrogen 
peroxide-induced up-regulation of HO-1 and GCLC proteins within 3h of hydrogen 
peroxide treatment.  Western blotting of HO-1, GCLC, and B-actin loading control after 
12h pretreatment with 0 or 20 µM quercetin aglycone followed by up to 24h treatment 
with 300 µM hydrogen peroxide.  Similar results were observed in 2 independent studies.   
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Figure 4.7.  Pretreatment with 20 µM quercetin aglycone alters hydrogen peroxide-
induced changes in phosphorylated ERK1/2, but not Nrf2 proteins.  Western blotting of 
Nrf2, phosphorylated ERK1/2, total ERK1/2, and B-actin or GAPDH as loading controls 
after 12h pretreatment with 0 or 20 µM quercetin aglycone followed by up to 24h 
treatment with 300 µM hydrogen peroxide.  Similar results were observed in 2 
independent studies.   
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Figures 
 
 
Figure 4.1.  Treatment during early differentiation (D5-9) with up to 300 µM hydrogen 
peroxide suppresses osteoblast phenotypic development.   
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Figure 4.2.  Acute treatment with 20 µM quercetin aglycone during early differentiation 
(D5-7) does not reduce alkaline phosphatase staining.  Representative wells of alkaline 
phosphatase stained cultures after treatment with up to 40 µM quercetin for 48h.   
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Figure 4.3.  Pretreatment with 20 µM quercetin aglycone prevents hydrogen peroxide-
induced suppression of alkaline phosphatase staining and preserves normal cell 
morphology.   
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Figure 4.4.  Pretreatment with 20 µM quercetin aglycone partially blocks hydrogen 
peroxide-induced suppression of osteoblast phenotypic gene marker mRNA.   
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Figure 4.5.  Pretreatment with 20 µM quercetin aglycone partially blocks up-regulation of 
HO-1 and GCLC mRNA and proteins after 4 days of hydrogen peroxide treatment. 
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Figure 4.6. Pretreatment with 20 µM quercetin aglycone partially blocks hydrogen 
peroxide-induced up-regulation of HO-1 and GCLC proteins within 3h of hydrogen 
peroxide treatment. 
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Figure 4.7.  Pretreatment with 20 µM quercetin aglycone alters hydrogen peroxide-
induced changes in phosphorylated ERK1/2, but not Nrf2 proteins.  
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CHAPTER V 
 
EPILOGUE 
 
 
Osteoporosis is a major public health concern that results in debilitating and 
expensive fragility fractures.  Because of the link between oxidative stress in osteoblasts 
and bone loss, preventive or therapeutic strategies targeting the osteoblast antioxidant 
response may improve bone health and prevent or reverse osteoporosis.  These studies 
have shown that quercetin metabolites up-regulate the antioxidant response of osteoblasts 
and this appears to “prime” cells for a subsequent oxidative stress event, which partially 
blocks hydrogen peroxide-induced up-regulation of the antioxidant response, while 
simultaneously preserving the development of the osteoblast phenotype.  These 
observations provide more evidence supporting a link between oxidative stress and 
dysregulation of osteoblast differentiation and function, as well as offer new insights into 
the osteoblast antioxidant response and the cellular effects of quercetin metabolites.   
While these studies have contributed novel observations of the osteoblast 
antioxidant response and phenotypic development in the presence of quercetin and in an 
oxidative stress environment, future studies are still needed to further elucidate 
mechanisms.   These studies have identified targets for this future research.   Two 
antioxidant response proteins, heme oxygenase-1 (HO-1) and γ-glutamate cysteine ligase 
(GCLC) were induced by quercetin, but the functional outcome of is still unknown, 
especially in the context of protecting the osteoblast phenotype during oxidative stress.  
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HO-1 was most robustly up-regulated by both quercetin and hydrogen peroxide.  
Furthermore, quercetin pretreatment blocked the expression of hydrogen peroxide-
induced up-regulation of HO-1, which suggests that the function of this protein is 
important to the osteoblast antioxidant response and may have important roles in 
protecting the osteoblast phenotype.  Higher levels of HO-1protein presumably increase 
heme catabolism and subsequently increase cellular levels of biliverdin, carbon 
monoxide, and iron.  Experiments to block HO-1 activity with inhibitors, such as zinc 
protophorphyrin, as well as experiments to target the metabolic byproducts would help 
establish the exact role of HO-1 activity in osteoblasts when they are exposed to 
quercetin and hydrogen peroxide and understand the extent that it is necessary for 
protecting the osteoblast phenotype.   
GCLC was also induced by quercetin, but this effect was delayed compared to 
HO-1.  Since GCLC is the rate-limiting enzyme in glutathione synthesis, it would be 
expected that up-regulated GCLC would lead to higher levels of glutathione.  Although 
alterations in total glutathione were not detected, quercetin may alter other aspects of 
glutathione metabolism in osteoblasts that were not assessed in these studies.  Future 
experiments would establish alterations in the ratios of oxidized to reduce glutathione, as 
well as the activities and expression of enzymes, such as glutathione peroxidase and 
glutathione reductase, that regulate the redox state of this thiol. 
In addition to functional outcomes of HO-1 and GCLC, the up-stream alterations 
in cell signaling pathways and transcriptional factors that mediate the effects of QRC and 
hydrogen peroxide bear further investigation.  Unexpectedly, these studies showed that 
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up-regulation of HO-1 and GCLC were not associated with cellular accumulation of 
Nrf2, which is thought to be classically involved in up-regulating antioxidant response 
genes.  Since this study did not examine Nrf2 transcriptional activity or post-
transcriptional modifications to Nrf2 or its sequestering protein, Keap1, the necessity of 
Nrf2 in up-regulating HO-1 and GCLC cannot be ruled out without further studies.  
Robust alterations in phosphorylated ERK1/2 were also observed in these studies.  
Quercetin pre-treatment appeared to delay hydrogen peroxide-induced ERK1/2 
phosphorylation, but resulted in up-regulation of phosphorylated ERK1/2 when cells 
were incubated in control media.  These differential effects suggest that ERK1/2 
signaling is involved in the antioxidant response and/or the preservation of the osteoblast 
phenotype in these conditions, but it is not yet clear of the exact role ERK1/2 plays in 
producing the outcomes observed here.  In the first study, NFκB was down-regulated by 
quercetin treatment alone, suggesting that quercetin may have anti-inflammatory effects.  
Although alterations of NFκB were not observed in the second study after treatment with 
hydrogen peroxide, the suppression of this transcription factor may play a role in the 
response of hydrogen peroxide to quercetin that depends on alterations in NFκB target 
genes that are altered after the 12h pretreatment.   
These studies also offer important insights into the behavior of quercetin itself.  
Although generally classified as an antioxidant, quercetin appears to produce both pro- 
and antioxidant effects on cells.  In fact, these studies indicate that quercetin may only act 
as an antioxidant in the context of a subsequent oxidative stress event, since quercetin 
treatment alone activated the antioxidant response.  Doses higher that 20 µM resulted in 
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down-regulation of the osteoblast phenotype, which suggests that in order to have 
protective effects on osteoblast differentiation outcomes, the dose must be low, or of 
short duration.  These studies primarily used 20 µM quercetin aglycone to induce HO-1 
and GCLC, but the cells did respond to lower doses of quercetin, and to the methylated 
metabolite, isorhamnetin.  Since the physiological levels of quercetin metabolites are 
lower it might be useful to design studies which expand the dose response of quercetin 
used in the pretreatment phase to include even lower doses and assess the effects of 
hydrogen peroxide.  Although this may not produce detectable alterations in protein 
levels of HO-1 and GCLC after the 12h pretreatment, there may be effects on the 
preservation of osteoblast phenotypic development.   
Although epidemiological findings and animal studies support the hypothesis that 
quercetin metabolites from dietary sources have a protective effect on bone health, the 
mechanisms by which this effect occurs remain difficult to establish.  This difficulty is 
due, at least in part, to the inherent challenges of translating physiological conditions to 
the in vitro setting.  First, quercetin is extensively modified by gut and liver enzymes, and 
a mixture of enzymatically modified metabolites is present in blood plasma.  The current 
studies have attempted to show a more inclusive picture of the effect of dietary quercetin 
at the cellular level, but the limited commercial availability of enzymatically altered 
metabolites (we only know of the three used in these studies) makes it difficult to design 
cell studies that fully capture the in vivo setting.  Second, since primary cells growing in 
vitro have been separated from their tissue microenvironments, it is impossible to 
completely account for all the factors that might influence treatment outcomes.  The cell 
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culture conditions may create an environment that makes the effect of lower doses of 
quercetin more difficult to detect, thus necessitating higher doses than those that have 
been recorded in blood plasma after consuming quercetin.  Finally, fetal rat calvarial 
osteoblasts undergo differentiation within a 2-week period after reaching confluence, 
which is in contrast to bone formation in remodeling adult bone, which takes months to 
complete and occurs at different stages in discrete packets all over the skeleton.  
Additionally, bone modeling occurs in young, growing individuals leading to peak bone 
mass early in adulthood, and high peak bone mass is protective of osteoporosis later in 
life.  Thus, it is difficult to fully replicate a lifetime of consuming quercetin or quercetin-
rich foods in the culture dish.  These limitations, however, do not preclude a direct role of 
quercetin metabolites as a preventive or therapeutic strategy, whether used 
pharmacologically, or at doses that are achievable through dietary intake.   
